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ABSTRACT

Pediatric osteosarcoma tumors are characterized by an unusual abundance of
grossly dilated endoplasmic reticulum and an immense genomic instability that has
complicated identifying new effective molecular therapeutic targets. Here we report a
novel molecular signature that encompasses the majority of 108 patient tumor samples,
PDXs and osteosarcoma cell lines. These tumors exhibit reduced expression of four
critical COPII vesicle proteins that has resulted in the accumulation of procollagen-I
protein within ‘hallmark’ dilated ER. Using CRISPR activation technology, increased
expression of only SAR1A and SEC24D to physiologically normal levels was sufficient to
restore both collagen-I secretion and resolve dilated ER morphology to normal.
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CHAPTER 1.

INTRODUCTION

Pediatric Osteosarcoma
Osteosarcoma (OS) is a malignant neoplasm of the bone that produces osteoid
tissue and arises in mesenchymal stem cells at least partially committed to the osteoblast
lineage [1]. The disease primarily affects adolescents 10 to 19 years of age,
disproportionately occurring in males during periods of rapid growth. OS tumors are
histologically subdivided and the most common occurrence is high-grade conventional
OS that represents around 80% of all cases and predominately appears in the
intramedullary cavity of long bones occurring about 42% in the femur, 19% tibia, and
10% humerus. The remaining occurrences split between the jaw or skull and the pelvis
bones [2, 3]. Much rarer classifications of OS accounting for about < 3% of cases include
telangiectatic, small cell and low-grade OS. Telangiectatic tumors have osteolytic
characteristics of producing minimal osteoid and forming necrotic cyst-like sacs[4].
Small cell OS tumors consist of small, round cells that produce malignant osteoid and
occasionally cartilage [5].While low-grade OS has high survival rate >90%, but is often
mistaken for fibrous dysplasia[6].
Prognosis has remained relatively unchanged since the 1980s. The 5-year survival
rate of non-metastatic OS falls around 60-70%, while metastatic disease is <20% and
most commonly occurs as pulmonary lesions (80-90%). At time of diagnosis 15%-20%
of adolescents will already present with metastatic disease and 40% of those with an
initial diagnosis of only a primary tumor will later develop metastases [3, 7].
Unfortunately, recurrent OS is fairly common (30-40%), and both primary and distant
disease have poor prognosis, similar to that of metastatic 5-year survival rates[8].
Prior to the 1980s, 5-year survival was < 20% for nonmetastatic OS patients.
Historically amputations were the method of treatment for OS, but despite this procedure,
the majority of patients still developed metastases and would succumb to the disease. It is
believed that most patients are presenting with micro-metastases during primary
diagnosis and this is why amputation alone was not sufficient to treat the disease [3]. To
address micro-metastases, current treatment plans include neoadjuvant therapies and
limb-sparing tumor resection, followed by post-operative chemotherapy. Patients with
localized tumors receive a very basic drug regimen of cisplatin, doxorubicin, and highdose methotrexate, whereas metastatic treatment additionally includes ifosfamide and
etoposide[9]. Unfortunately, the use of all of these chemotherapeutic reagents is
associated with acute and often long term toxic effects including neutropenia,
thrombocytopenia, hypophosphatemia, mucositis, cardiac dysfunction, renal dysfunction,
and long term hearing loss and infertility[3, 10].
There has been minimal improvement to the chemotherapy regimen and
subsequent 5-year survival rates over the past 40 years that has been attributed to the
genetic complexity associated with the disease preventing genome-informed therapy. OS
tumor cells are plagued by extreme chromosomal instability and gene copy number
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variations that results in intra- and inter-tumor heterogeneity[11]. The advent of whole
genome sequencing (WGS) has led to the identification of a few drivers, of which most
frequently reported are tumor protein P53 (TP53) (~95%) and RB transcriptional
corepressor 1 (RB1) (~50%) in which inactivation occurs either by structural
rearrangement, deletion or mutation[11-13]. Even with the advancement of identifying
candidate drivers and disrupted pathways the etiology of OS still mostly remains a
mystery and there has yet to be a defined molecular pattern other than wide-spread
genomic instability that is observed in the majority of patients. Yet, despite this genetic
complexity, in the 1970s electron microscopy studies revealed an abundance of grossly
dilated endoplasmic reticulum (ER) full of electron dense material. This morphology has
been noted as the most prominent characteristic of every OS patient tumor sample across
multiple studies [14-16].

The Secretory Pathway

The endoplasmic reticulum
As the largest organelle in a cell, the ER spans outward from the nuclear envelope
a bilayer network of sheets and tubules that serves as site of many cellular processes
focused primarily around protein and macromolecule synthesis [17]. Approximately onethird of all transcribed genes encode proteins that are destined to either be secreted, act as
an integral membrane protein, or become an ER or Golgi apparatus resident protein.
Guided by ER localization sequence, ribosome complexes dock on protein transport
protein SEC61 (SEC61) translocons along the peripheral membrane of the ER and will
translate peptides directly into the luminal space. Nascent transmembrane peptides
contain hydrophobic regions which are transferred lateral directly into the phospholipid
bilayer [18]. During translation into the ER the peptides are bound by molecular
chaperones and enzymes begin to act upon the nascent protein immediately.
There are two main molecular chaperone families that govern protein folding
within the ER, the heat-shock proteins (HSP) and the lectins[19]. Resident ER heat-shock
chaperone, Immunoglobulin Heavy Chain-Binding Protein (BiP) uses binding cycles
powered by ATP hydrolysis to target and protect hydrophobic regions prone to
aggregation and prevent premature folding. BiP is fairly promiscuous chaperone with
binding-sites occurring about every 40 amino acids on average in proteins. Folding
reactions are highly regulated via cofactors like SIL1 Nucleotide Exchange Factor (SIL1)
and Hypoxia Up-Regulated 1 (GRP170) that stimulate release of the adenosine
nucleotides, but also by DnaJ proteins that can accelerate the hydrolysis cycles and
sometimes directly interact with clients [20]. There are also an abundance of resident
enzymes that support folding reactions through post-translational modifications.
First, oligosaccharyltransferases will add N-linked glycans to asparagine residues
that will improve stability of the protein by protecting hydrophobic regions increasing
thermostability. Then conversely, there are also glucosidases that will rapidly trim these
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newly added glycans. The lectin family chaperones, calnexin and calreticulin specifically
interact with these glycoproteins, stabilizing and supporting folding reactions into the
correct tertiary state, similar to BiP. The oxidizing environment of the ER and numerous
enzymes that function to assist proteins to reach their correct tertiary state. Two of which
are disulfide isomerase that catalyzes disulfide bond formation and prolyl peptidyl cis–
trans isomerases altering structures and supporting macromolecule assembly[19].
ER quality control is critical to preventing disease states by blocking the export of
misfolded clients. If correct folding states cannot be achieved, these proteins are targeted
for ER-associated degradation (ERAD). ERAD occurs by retrotranslocation of the
terminally misfolded clients into the cytosol where they are ubiquitinated and rapidly
degraded by the proteosome. If large aggregates accumulate that cannot be disposed of
through ERAD, autophagy can occur. Briefly, clustering and interaction of special ER
receptors and proteins alter membrane morphology by clustering the ER tubules favoring
them to separate off into autophagosomes which will fuse with lysosomes facilitating
protein degradation and ER membrane turnover[21]. Finally, correctly assembled and
thoroughly chaperoned secretory cargo are packaged into coat protein complex II
(COPII) vesicles for unidirectional anterograde transfer to the Golgi apparatus along
microtubules carried via dynein/dynactin motor activity[22].
Macromolecule cargo ― Procollagen I
Collagen-I makes up >90% of the secreted organic bone matrix, osteoid. To date
twenty-eight different collagen proteins have been identified, but type-I collagen remains
the most abundant extracellular matrix protein present in the human body. Collagen-I
takes a tertiary structure as a right-handed triple helix, composed from three subunits of
two 1 chains and one 2 chain[23]. All collagens are characterized by a tripeptide
repeat of either Gly-Pro-X or Gly-X-Hydroxyproline and X can be any residue, but are
often lysine[24]. The concentration of these three amino acids, glycine, proline and
hydroxyproline found in collagens as a repetitive motif supports the tensile strength of
the helical structure due to the post-translational modifications inflicted on the side chains
of the amino residues. Throughout collagen-I, the motif repeats occur for about 1000
amino acids and are flanked on each side by non-collagenous, N- and C-terminal globular
domains [25].
The type-1 collagen chains are transcribed from two separate genes, collagen
alpha-1(I) chain (COL1A1) and collagen alpha-1(II) chain (COL1A2), and are cotranslationally synthesized directly into the ER as propeptides. As with all proteins that
traverse the ER, the collagen monomers are bound by ER chaperones to prevent
aggregation and support post-translational modifications and folding reactions. After
signal peptide cleavage, the first step of modifications is the hydroxylation of select
proline and lysine residues, catalyzed by hydroxylase enzymes. Hydroxylation of the
prolines contributes to the stability of the protein by creating intramolecular hydrogen
bonds, while hydroxylation of lysine allows stable cross-linking of the collagen
heterotrimers and later in a larger context of supramolecular fibril formation. Following
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this, the hydroxylysines are often glycosylated by resident enzymes, but both these posttranslation modifications occur prior to tri-helical assembly[24]. Numerous chaperones
such as BiP, Heat Shock Protein 90 Beta Family Member 1 (GRP94) and occasionally
collagen specific chaperone, Serpin Family H Member 1 (HSP47) cycle through binding
the monomers to stabilize the peptides during this time, preventing aggregation of the
peptides numerous hydrophobic regions.
Finally, the alignment of the C-terminal domains form a globular structure
stabilized by protein disulfide-isomerase (PDI) catalyzed inter- and intrachain disulfide
bond formation and isomerases resulting in formation of the triple -helix that assembles
from the C- terminus towards N-terminal domain in a zipper fashion [25]. HSP47
proteins are described as a collagen-specific guide and knockout is embryonic lethal[26].
These chaperones favor the tertiary triple-helix structure of procollagen, recognizing
arginine residues for binding and are critical to preventing aggregation of the procollagen
trimers within the ER and to the incorporation of these inflexible proteins within COPII
mega vesicles for trafficking to the Golgi apparatus[27].
Procollagen-I is a large, rigid protein coming in around 300nm in length and
1.5nm in diameter [24]. Traditionally, the COPII vesicles responsible for trafficking
secretory granules to the Golgi apparatus were observed to be 60-80nm in diameter and
considered much too small for procollagen-I transfer. In 2013 James E. Rothman, Randy
W. Schekman and Thomas C. Südhof received a shared Nobel Prize in Physiology or
Medicine for their discoveries in machinery regulating vesicle traffic in cells. It was
Sheckman’s early work in S.cerevisiae that led the way for understanding the basics of
COPII biogenesis in mammals[28]. Yet, as evidence was discovered that supported the
cisternal maturation hypothesis of how procollagen-I proceeded through the Golgi
apparatus, it still remained a mystery of how a such a large protein was trafficked from
the ER to the Golgi[29].

COPII tubules
COPII endomembrane biology is believed to be conserved as far back as the Last
Eukaryotic Common Ancestor (LECA), the first to give rise to all eukaryotic cells [30].
The COPII coats consist of seven core proteins; GTP-binding protein SAR1 (SAR1),
protein transport protein Sec23 (SEC23), protein transport protein Sec24 (SEC24),
protein SEC13 homolog (SEC13), protein transport protein Sec31 (SEC31), prolactin
regulatory element-binding protein (SEC12) and protein transport protein Sec16
(SEC16). Comparative genomic analyses found the presence of at least one ortholog of
the core first five COPII subunits, respectively to be broadly conserved across
eukaryotes. SEC12 and SEC16 proteins appear missing in some eukaryotic taxa, but
these may have been more difficult to identify due to sequence divergence and evidence
does suggests that all seven subunits were present in the LECA[31].
In multicellular organisms, gene duplication events of COPII genes and other
membrane-trafficking genes are prevalent, however three paralogs of SEC24 appear to
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have been present in the LECA[30, 31]. SEC24 proteins function as cargo adaptors, each
with multiple binding sites expanding the complexity and specificity of the cargo
selection in these vesicles. In humans, there are four isoforms of SEC24A-D[32].
Genomic analyses group SEC24A and B together and separately from the grouping of
SEC24C and D, suggesting each of these clades to represent a SEC24 lineage present in
the LECA that went through a duplication event. Interestingly, the third SEC24 paralog
present in the LECA, while not conserved in vertebrates appears to have continued
lineage in plants[31].
In mammals, conventional COPII biogenesis begins at ER exit sites (ERES)
marked by the presence of, transmembrane bound, guanine nucleotide exchange factor
(GEF) SEC12 proteins and SEC16 scaffolding. In a stepwise fashion the initiation of
vesicle formation begins with the recruitment of small GTPase SAR1 proteins by the
SEC12 (GEF). The GTP bound form of SAR1 leads to a conformational change and
results in the embedding of a small amphipathic -helix into the cytosolic side of the ER
membrane. Docked SAR1 initiates the pre-budding process, quickly binding to SEC23
proteins of the heterodimer SEC23:SEC24 complexes. SEC23 proteins further regulate
SAR1 activity as a GTPase activating protein (GAP), while SEC24 proteins function as a
cargo receptor and adaptor, binding proteins both directly and indirectly. As of 2016 as
many as twenty four other cargo receptors and adaptors have been identified in
mammalian cells, facilitating the inclusion of a diverse range of cargo needs in more
complex tissue types[33]. Finally, the outercoat SEC13:SEC31 heterotetramer complexes
bind to the inner coat pulling together multiple pre-budding complexes, assembling into
cage-like structures forming a spherical COPII vesicle. Scission of these vesicles from
the ER is complex and still somewhat up to debate. Initially it was believed that SAR1
proteins controlled vesicle scission solely through GTP hydrolysis leading to removal of
their docking into the ER membrane. The model currently most favored is that the
insertion of SAR1 -helix into the bilayer initiates curvature and subsequent membrane
deformation. SEC12 proteins function to recruit an abundance of SAR1, concentrating
the proteins at ERES and the binding of the SEC23:SEC24 and SEC13:SEC31 coat
complexes pull the membrane curvature into a bud. It is proposed the combination of
membrane curvature leading to bilayer asymmetry and SAR1-GTP hydrolysis occurring
at the base of this bud combines efforts resulting in vesicle scission[34, 35].
Due to the size discrepancy of COPII diameter and collagen length, it wasn’t until
2002 that COPII vesicles was first implicated in the trafficking of procollagen from the
ER by evidence from fluorescent studies identifying procollagen-I in YFP-SEC24D
labeled structures. Furthermore, the use of a SAR1A mutant unable to hydrolyze GTP led
to an accumulation of procollagen-I within the ER, reminiscent to what is observed in OS
tumor cells [36]. However, it wasn’t until 2006, when an RNA interference screen run on
Drosophila cells led to the identification of transport and Golgi organization protein
(TANGO1) and family members, which turned out to be the missing puzzle piece to
explain how these vesicles accommodate such a large cargo[37].
TANGO1 is an integral transmembrane protein localized to ERES. It’s C-terminal
extends into the cytoplasm and contains a proline-rich domain that can bind to both
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SEC23 and SEC16 scaffold proteins and coiled-coil domains that interact with both
ERGIC membranes and cTAGE5 binding partner. The ER lumenal side of TANGO1
contains an SH3 domain, which can directly bind to collagen chaperone HSP47
facilitating the inclusion of the unusual cargo into COPII vesicles[38]. In addition to
TANGO1, a closely related homolog, melanoma inhibitory activity protein 2 (cTAGE5)
was discovered to assist in the formation of these mega vesicles capable of transporting
procollagen. cTAGE5 is also an integral membrane protein localized at ERES that shares
a lot of structural characteristics with TANGO1, appearing as almost a truncated version
of it, missing the extended N-terminal lumenal region. It’s C-terminal side is located
facing the cytoplasm, where it contains a proline-rich domain capable of interacting with
SEC23 and two coiled-coil regions that can interact with both TANGO1 and SEC12
proteins. Unlike, its sister protein cTAGE5 contains a very short ER lumenal region that
holds the ER localization sequence. Studies involving cTAGE5 mutants have
demonstrated the protein as being critical to the localizing of SEC12 at ERES. The nonfunctional mutants lead to the inability to secrete collagen-VII from the ER, but
interestingly could be rescued by overexpressing SAR1 protein. This data suggests that
cTAGE5 is critical for the concentrating of SAR1 proteins to initiate pre-budding
complexes, via its localizing SEC12 to ERES[39].
Recently it has been demonstrated that the inclusion of TANGO1:cTAGE5 does
not only function as procollagen receptor, but additionally alters the stoichiometry of the
COPII coats supporting a helical tubular structure conducive to large cargo packing
(Figure 1-1). These large carriers contain the conventional seven core COPII proteins,
but additionally include transmembrane TANGO1 proteins anchored at ER exit sites to
SEC16 scaffolding protein and cTAGE5 proteins, that bind SEC12, forming a
SEC16:TANGO1:cTAGE5:SEC12 complex. The ER lumenal portion of TANGO1
proteins act as a cargo receptor, binding to procollagen indirectly though adaptor HSP47
tethering the large cargos within the assembling mega-vesicles. While cytosolically,
domains of the cTAGE5:TANGO1 proteins are able to interact with the SEC23 portion
of the SEC23:SEC24 heterodimers effectively delaying the outercoat SEC13:SEC31
interaction. The binding of the outercoat SEC31 proteins position SEC23 (GAP) to better
influence SAR1 GTP hydrolysis leading to vesicle completion and fission[40]. The
TANGO1:cTAGE5 proteins are capable of bridging at least four SEC24:SEC23-SAR1A
pre-budding platform interactions stabilizing the lattice structure and propagating tubular
growth. It was found that SEC13:SEC31 outercoat binding increases the GAP activity of
SEC23 by almost 10-fold[41]. Therefore, it is hypothesized that the TANGO1:cTAGE5
interaction with SEC23 (GAP) effectively delays the outercoat heterotetramers binding to
the inner coat coordinating extended vesicle growth for efficient collagen export from the
ER[42]. Additionally, it has been demonstrated that ubiquitin ligase cullin-3 (CUL3) acts
upon SEC31 with assistance of its adaptor, kelch-like protein 12 (KLHL12). Although
SEC31 monoubiquitination does not appear critical to smaller vesicles, knockdown
studies have proved it as essential for the secretion of collagen proteins. It is not exactly
clear how this modification alters COPII vesicle structure, but it is proposed that it may
either delay budding or promote coat polymerization of these mega carriers[43].
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Figure 1-1.

COPII mega-tubule formation facilitates the export of procollagen-I.

(A) COPII mega-tubules assemble to accommodate trafficking of large procollagen
proteins. ER exit sites are marked by complexes of SEC12:cTAGE5:TANGO1:SEC16
proteins. The lumenal region of TANGO1 acts as a procollagen adaptor tethering the
cargo to the vesicles via interactions with HSP47. Externally, SEC12 (GEF) recruits
SAR1A resulting in conformational change and shallow implantation of into the
cytosolic ER membrane. Docked SAR1 recruits inner coat complexes SEC23:SEC24 to
bind. The addition of TANGO1 supports the mega vesicle formation by bridging
SEC23:SEC24:SAR1 complexes to alter the stoichiometry and geometry into a tubule
formation and delaying outer-coat interactions for extended growth. Binding of the outercoat complexes SEC13:SEC31 influences SEC23 (GAP) activity upon SAR1,
accelerating vesicle scission.
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SAR1
In general, SAR1 GTPases are very well conserved throughout evolution, even
sharing an almost 80% amino acid homology with yeast. Most vertebrates express two
isoforms of the protein and as with other COPII proteins it is hypothesized that expansion
to multiple paralogs would facilitate to the greater diversity of secretory requirements for
more complex tissue types[31]. Human SAR1A and B are almost 90% identical yet have
been demonstrated to have functional differences. Most notably, SAR1B loss is
associated with the inability to secrete chylomicrons from the endoplasmic reticulum
leading to chylomicron retention disease. SAR1B is the predominately expressed isoform
detected in intestinal cells but patients who exhibit loss of this protein are often found to
have increased expression of the SAR1A paralog, yet despite sequence overlap this
isoform cannot compensate [44]. Biochemical analysis of theses GTPases sheds some
light on their differences, and it was discovered that SAR1A exchanges GTP more
rapidly, has a higher affinity for homodimerization and binds to SEC31 more strongly
than its sister protein. SAR1B structural difference allows slower GTP exchange and a
high affinity to bind SEC23, a GAP protein that regulates SAR1 activity. It is proposed
that this is to allow a slow controlled, and more extended packaging of extremely large
chylomicron cargo and is why SAR1A is incapable of compensating for the loss.
Conversely, in tissues that experience an abundant secretory demand a more rapid
vesicle secretion is required to maintain homeostasis and here SAR1A would function
better [45, 46]. The critical requirement of mammalian SAR1 proteins to COPII vesicle
assembly was highlighted by siRNA mediated SAR1A and B dual depletion in HeLA
cells. Results revealed a scattered expression of the COPII binding partners further
concreting SAR1 as the protein responsible for initiating the budding of COPII formation
by binding ER membrane and recruiting SEC23:SEC24 complexes. Furthermore,
knockdown of the two isoforms in fibroblast cells inhibited the export of procollagen-I
and resulted in a dilated ER morphology, similar as to what is observed in osteosarcoma
patient samples[47]. In corroboration of these findings, a knockdown screen targeting
COPII genes individually in fibroblast cells lead to a >50% reduction in collagen-I
secretion as a result of SAR1A loss, but not SAR1B, highlighting a potential isoform
specificity for procollagen-I packaging [48].
SEC24
Early in vesicle trafficking discovery it was assumed that protein cargo were
incorporated by nonselective bulk flow[49]. However, it quickly became evident that
specific cargo were being concentrated in vesicles by selective incorporation, while the
majority of ER resident chaperones remained ER localized suggesting export as being at
least partially regulated[50]. Early studies using yeast mutants led to the identifications of
COPII coat proteins because they disrupted ER to Golgi transport. S. cerevisiae were
discovered to contain three Sec24p isoforms. Mutant studies identified one Sec24p to be
essential for growth, while the functional loss of the other two only resulted in defective
secretion of specific proteins. So, when mammalian SEC24 counterparts were found to
express four genes that share sequence homology with S. cerevisiae Sec24p it was
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assumed they too would help select cargo[51-53]. Secretory proteins rely on signal
mediated sorting for packaging, and SEC24 proteins have been recognized to contain
multiple binding sites with preferences for specific residues, broadening the diversity of
cargo these adaptors could potentially interact with[32]. As previously mentioned,
SEC24A and B are believed to have duplicated from the same gene and SEC24C and D
from another originating from the LECA. Studies have demonstrated that residues lining
the binding pockets of SEC24A and B are highly conserved, as are SEC24C and D. It has
been determined there are very subtle changes that result in different binding capacity of
the two proteins within each group. However, other than the ability to bind SEC23
proteins, there appears to not be much overlap between the two groups of SEC24[54]. In
the context of procollagen transport SEC24D has been observed to be critical for the
secretion of extracellular matrix proteins. A zebrafish bulldog mutation was discovered to
prevent function of the Sec24d protein disrupting craniofacial development. Chondrocyte
cells effected by this mutation presented with an accumulation of procollagen-II, their
primary expressed collagen type, within grossly distended ERs. Analyses found other
structural matrix proteins to be effects as well, but membrane receptors like 1-integrin to
be transported as normal. Additionally, despite the shared homology between Sec24D
and Sec24C, knock down of Sec24C did not affect collagen secretion in the
chondrocytes, nor could fully compensate for Sec24D bulldog mutant. Taken together
data suggested cargo specific roles for Sec24D protein[55]. In mice, Sec24d gene
disruption proves to be embryonic lethal. Though it remains unknown if this is because of
temporal expression of specific Sec24 proteins during development that prevents the
ability of compensation by SEC24C[56]. Interestingly, the same targeted siRNA
knockdown screen of COPII genes that found SAR1A protein to critical to collagen-I
secretion, also indicated SEC24D, but not its sister isoforms [48].
SEC23
SEC23 proteins interact with SEC24 to form a heterodimer complex that
constitutes the inner coat of COPII vesicles. Early on these protein were identified as a
GTPase-activating protein capable of stimulating SAR1 GTPase activity by 10 to 15
fold[57]. The mammalian genome encodes two paralogs of SEC23 that share about 85%
amino acid sequence identity and while functionally have been declared
indistinguishable, mutations in both are associated with very different coatopathies[58].
Reminiscent to the phenotypic effects of the zebrafish Sec24d bulldog mutant, in humans
a rare mutation effecting the SEC23A causes Cranio-lenticulo-sutural dysplasia. These
patient’s fibroblasts show significant accumulation of procollagen-I within a distended
ER and defective matrix protein secretion resulting in skeletal deformities[59]. Mutant
sec23A gene expression during zebrafish development similarly resulted in cranial
dysmorphia and prevented the secretion of collagen-II from chondrocytes leading to a
sparse extracellular matrix. The knockdown of zebrafish sec23B resulted in similar
morphological effects on skeletal development, even though in humans SEC23B
functional loss is not associated with skeletal dysplasia[60]. Instead, mutant SEC23B
genes are associated with congenital dyserythropoietic anemia type II suggesting tissuespecific expression during erythrocyte development[61]. Yet, functional studies in both
mice and zebrafish have demonstrated the SEC23 paralogs are able to rescue mortality of
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gene disruption caused by the loss of the other paralog[58]. Together these data suggest
there is significant functional overlap between the paralogs and that disorders may be
caused by tissue and temporal-specific expression of isoforms.
SEC13 and SEC31
The COPII outer coat is comprised entirely of heterotetramer SEC13:SEC31
complexes forming lattice-like cage structures. SEC13 is one of few COPII genes that
hasn’t appeared to have gone through a duplication event. It also uniquely has a dual
functions as a scaffolding protein for the nuclear pore complex (NPC). Structurally the
NPC takes on a somewhat spherical shape with curved membranes, similar to COPII
vesicle morphology, leaving it somewhat unsurprising that SEC13 moonlights as scaffold
support in the NPC as well. It is hypothesized that many of the NPC proteins share
ancestry with COPII subunits[62]. Similar to loss observed of other COPII genes, mutant
Sec13 in zebrafish leads to cascading effects from disrupted ER morphology, sparse
matrix deposition and activation of the unfolded protein response that eventually results
in cell death. Sec13 knockout is embryonic lethal and mutants have been demonstrated to
effect multiple tissue types such as chondrocytes, intestinal cells, and hepatocytes [63].
Binding partner, SEC31 is encoded as two paralogs in mammals that share about 47%
sequence homology and are ubiquitously expressed, but specific tissue types contain
higher expression of certain paralogs [64]. SEC31A knockout studies in zebrafish
revealed disrupted development and resulted in chondrocytes with grossly distended ER
full of procollagen-II protein[63]. Functional differences between SEC31A and B have
not been completely characterized, but a targeted siRNA screen revealed SEC31A
knockdown led to >50% reduction in collagen-I secretion from fibroblast, while
knockdown of its paralogue did not have this effect[48]. It still remains to be elucidated if
the loss affected collagen secretion because of functional differences or temporal
regulation and/or tissue expression variabilities.
SEC12 and SEC16
SEC12 glycoproteins are encoded by a single gene that remains highly conserved
in yeast, mice, Drosophila, and humans [65]. It was first identified and characterized in S.
cerevisiae as an ER localized transmembrane protein that functions as a guanine
exchange factor stimulating SAR1 bound to GDP to exchange for GTP powering a
conformational change and facilitating implantation into the ER membrane [66, 67].
Mammalian SEC12 structure contains a large cytoplasmic domain supporting it’s GEF
activity and a small lumenal region containing ER localization signal sequence[68]. The
cytoplasmic domain has been reported to act as a transcription factor, known as prolactin
regulatory element binding protein and in fact has more extensively characterized as a
transcription factor[65]. Regulation of COPII gene transcription is still a mostly
unexplored field, with only a few key transcription factors identified. Yet, current
research has yet to identify SEC12 as a COPII gene regulator.
SEC16 is demonstrated to be both a critical scaffold protein interacting with
numerous COPII proteins and negative regulator of SAR1 GTPase. First characterized in
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budding yeast mutant Sec16p resulted in dispersed COPII subunits that would not
localize at ERES. Furthermore, it was demonstrated to be responsible for ERES
organization because the use of dominant-negative Sar1 mutants prevent vesicle
secretion, but did not disrupt COPII protein localization unlike mutant Sec16p[69]. There
are two paralogs present in mammals. SEC16A encodes a large ER localized
transmembrane protein with a domain near the C-terminal that is conserved in yeast
Sec16p and demonstrated to bind other coat proteins. SEC16B encodes a smaller protein
that lacks the C-terminal conserved domain, but immunofluorescent studies show colocalization of both paralogs at ERES and both appear ubiquitously expressed in all tissue
types[70]. SEC16 proteins have evolutionarily maintained two other domains as well.
One is centrally located and is present in both paralogs of mammalian SEC16 and the
third is referred to as the ERES localization domain, but in Drosophila was demonstrated
to require the central conserved domain as well to correctly localize at ERES [71].
Despite sharing two conserved domains the two paralogs have been characterized as
functionally nonredundant. SEC16A can interact with SEC23 through the conserved
domain near the C-terminal that is missing in SEC16B. However, the protein is capable
of binding both SEC24 and SEC31 with the central conserved domain. Suggesting
SEC16B will not be able to interact with SEC23 but can with the other coat proteins.
siRNA mediated knockdown studies involving either paralog results in disrupted ERES,
so despite structural differences they are both critical to its organization[72]. Coat
dynamics are still somewhat unclear surrounding SEC16 because it is capable of
interacting with numerous COPII proteins. Yet, It has been proposed that SEC16:SEC23
and SEC16:SEC31 interactions interfere with the ability of SEC31 outer-coat protein to
bind to SEC23, acting as a negative regulator of SAR1 GTPase and subsequently
prolonging the coat assembly period [73]. This regulatory activity makes sense in context
to procollagen-I secretion because recently it was discovered that ERES stability requires
SEC16 and TANGO1 procollagen-I receptor. Their interaction organizes ERES and loss
of either dissembles COPII subunits. SEC16 is a cytoplasmic protein, so it is logical that
without integral membrane protein, TANGO1 it cannot localize to ERES to act as a
scaffold in support of other COPII proteins[74].
Next stop ― The Golgi apparatus
After COPII vesicles have parted from the ER they begin homotypic fusion with
one another forming vesicle tubular clusters, now more commonly referred to as the ERGolgi intermediate compartment (ERGIC)[75]. In the formation of mega-tubules to
transport procollagen-I, TANGO1 actually interacts with receptors recruiting ERGIC
membranes to use in assembly of these extra-large vesicles[76].Formation of the ERGIC
is complex and involves a number of proteins that regulate the processes including Rab
GTPases and number of tethering complexes[77]. However, most critical to the fusion are
vesicle transport through interaction with t-SNAREs homolog (SNAREs). As
transmembrane proteins SNAREs are packaged into COPII vesicles during assembly.
Best characterized in S. cerevisiae, uncomplexed SNARE proteins have been detected
bound to Sec24p cargo receptor, linking COPII vesicle and fusion mechanisms
together[78]. Dependent on cell type, v-SNAREs that contain (one -helix) and t-
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SNAREs with (three -helices) are selectively packaged into COPII vesicles by SEC24
cargo adaptor proteins. These v- and t-SNAREs sharing a COPII vesicle interact forming
a complex of a four-helix bundle. N-ethylmaleimide-Sensitive Factor (NSF) disrupts this
complex attaching via its binding partner a-SNAP. Using ATP hydrolysis to power itself,
NSF is able to essentially untwist the helix bundle, which frees the v- and t-SNAREs to
interact with SNAREs on identical membranes of other COPII vesicles. These complexes
bring adjacent COPII vesicles near enough in proximity to support homotypic membrane
fusion resulting in the ERGIC formation which is transported along microtubules via
dynein/dynactin motor activity towards cis- Golgi[75, 79].
The Golgi apparatus morphologically appears as narrow ribbons of cisternae
stacked upon one another. These compartments exist as an ordered series with the cisface adjacent to the ER or ERGIC and the exit or trans- side facing the plasma
membrane. Proteins traversing the Golgi apparatus enter the cis- face and will be
modified by various glycosidases, glycosyl transferases and other resident enzymes that
are majority membrane bound along the organelles within specific cisternae
compartments, unlike the soluble ER resident proteins. The primary post-translational
modification that proteins will endure are O-linked glycosylation on serine or threonine
residues, sulfation and phosphorylation. Specifically for procollagen-I timers, they are
further modified by the addition of O-linked glycosylation near the C- and T-terminal
globular domains before exocytosis or vesicle mediated release into the extracellular
matrix[80]. However, the method of protein transport through the cisternae stacks has a
long history of debate[81].
Initially, it was thought that small soluble proteins transverse the Golgi
compartments in an anterograde fashion via vesicles budding from each cisternae for
transfer to the next[82]. Yet, similar to the early mystery of transporting large collagen
proteins from the ER when traditional COPII vesicles were much too small, it remained
unknown how large rigid proteins would be processed through the Golgi, as they too
exceeded the cisternae vesicle size. However, in 1998 evidence was discovered that
supported the cisternal maturation model when scientists observed procollagen-I
transverse cisternae stacks without vesicle-mediated transport [29]. This model proposes
that ER derived COPII vesicles fuse with cis- Golgi and receive recycled cis- Golgi
enzymes from the previous cis-cisternae forming a new cis- compartment. This
simultaneously progresses the previous cis- cisternae forward in the process to become
medial cisternae receiving a change in resident enzymes for the next step of protein
modifications. This anterograde process continues along promoting each cisternae to the
next phase until becoming a trans- Golgi compartment in which it will divide into cargo
carriers transporting proteins to endosomes or the plasma membrane[83]. Furthermore,
modification of procollagens into mature proteins begins while traversing the Golgi
apparatus. The proteins are altered by furin proprotein convertases near the terminal
regions. Additionally, once transported extracellularly the procollagens are processed into
a final mature protein by the cleavage of the globular N- and C- terminal regions by a
disintegrin and metalloproteinase with thrombospondin motif (ADAMTS) and tolloid
enzymes. The final cleavage of the terminal ends allows self-assembly into a fibril
form[84, 85].
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The unfolded protein response
The luminal space of the ER is typically maintained around 50nm in eukaryotes,
but the shape and volume of ER can dramatically shift depending on the needs of a cell
[16]. For instance, plasma cells secreting an abundance of antibodies experience a very
high secretory demand and to cope the cells increase their ER volume more than 3-fold.
The cells expand ER membrane and increase chaperones, resulting in a very organized
tightly stacked ER structure that often extends throughout any free space within the entire
cell [86]. The dilated ER morphology observed in OS greatly surpasses the 50nm luminal
spacing typically observed in cells. Pre-osteoblast cells, the progenitors of OS, similarly
experience a high secretory demand due to the secretion of osteoid. Yet these cells
maintain a normal ER structure, unlike OS tumor cells, whose dilated ER is more similar
to a cell dealing with an accumulation of unfolded protein. The unfolded protein response
(UPR) is an ER localized signaling cascade that functions to sense and maintain
homeostasis within the organelle (Figure 1-2). In mammalian cells there are three
transmembrane proteins that monitor stress with their ER-lumenal regions:
Serine/threonine-protein kinase/endoribonuclease IRE1 (IRE1), Eukaryotic translation
initiation factor 2-alpha kinase 3 (PERK), and Cyclic AMP-dependent transcription
factor ATF-6 (ATF6).
IRE1, an ER-membrane localized serine/threonine kinase and endoribonuclease
and it is best characterized because it is the only UPR branch present in budding yeast.
There are two proposed methods for IRE1 activation, the first is that upon accumulation
of increased protein synthesis or misfolded proteins BiP is titrated away from IRE1
allowing it to oligomerize and activate. However, it has also been proposed that IRE1 is
able to directly bind unfolded proteins due to a stretch of conserved peptides similar to
the binding region of the major histocompatibility complex[87]. Once IRE1 monomers
are free to oligomerize, it positions their kinase domains in close enough proximity
resulting in trans-autophosphorylation, which activates endonuclease activity in its Cterminus. The IRE1-RNAse has a direct target of X-box binding protein 1 (XBP1)
transcript. When targeted it will excise 26 nucleotides from forming a splice variant,
XBP1(S). The splice variant is translated as a transcription factor protein upregulating
transcription of specific genes to support folding, secretion, ERAD, and lipid biosynthesis
pathways. In addition to XBP1 splicing, IRE1 facilitates regulated IRE1-dependent decay
where it cleaves both mRNAs and microRNAs resulting in a reduced protein load within
the ER[88].
Similar to IRE1, it is believed that BiP remains bound to PERK in times of low
folding demand and that the increased translation of proteins titrates away the chaperone
activating signal transduction [89]. The PERK protein is a kinase and when released will
oligomerizes and trans-autophosphorylate. However, while IRE1 only phosphorylates
itself, PERK acts to phosphorylate eukaryotic translation initiation factor-2a (eIF2a)
which globally attenuates cap-dependent protein translation reducing the influx of
proteins destined to enter the ER. However, transcript Cyclic AMP-dependent
transcription factor ATF-4 (ATF4) escapes translational repression and will translocate to
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Figure 1-2.

UPR signaling cascade downstream targets.
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the nucleus where it will activate a set of UPR gene including targets like amino acid
metabolism and autophagy. Additionally, ATF4 works in a feedback loop where it
upregulates Protein phosphatase 1 regulatory subunit 15A (GADD34) to dephosphorylate
eIF2a and restore protein synthesis[87, 88].
ATF6 is proposed to be bound by BiP in its lumenal domain during periods of
inactivation like the other UPR mediators and that BiP titration unmasks a Golgilocalization sequence. However, recently it has been conversely proposed that ATF6 is
actually continually synthesized and degraded until the balance of ER homeostasis is
tipped preventing degradation and resulting in transport [90]. ATF6 activation is
mechanistically very different from the other two UPR signal mediators. It requires the
protein to be packaged into COPII vesicles and transported to the Golgi apparatus where
it will be cleaved by site-1 and site- 2 proteases releasing its cytosolic domain as an
active transcription factor. Active ATF6 will translocate to the nucleus and activate a
third set of UPR targets, increasing ER chaperones, XBP1 transcripts, and ERAD
components. The three UPR signal transducers operate in parallel to reduce the protein
load in the ER, assist to increase its capacity to handle the accumulation of misfolded or
unfolded proteins and finally if homeostasis cannot be restored to trigger apoptosis.[87,
88]
CREB3L1/OASIS
In addition to the traditional UPR response there is the CREB3 family of proteins
that are localized in a more tissue specific manner. These proteins have a wide range of
functions from playing critical roles during differentiation and development to
tumorigenesis. Osteoblast cells highly express ER transmembrane localized, Cyclic
AMP-responsive element-binding protein 3-like protein 1 (CREB3L1/OASIS), that
shares ~31% homology to ATF6 in its cytosolic N-terminal region [91]. Unlike other ER
stress transducers, the lumenal region of CREB3L1 is not bound by ER chaperones
during periods of non-stress, but instead these proteins are consistently turned over by the
proteosome. The occurrence of stress stabilizes the proteins and translocation to the Golgi
results in site-1 and site-2 proteases into an active transcription factor that regulates a
number of downstream genes, like collagen-I transcript, COL1A1. Similar to what has
just recently been proposed for ATF6 inactivation/activation. Additionally, while it
remains to be proven we assume the OASIS proteins are packaged into COPII vesicles
for ER-Golgi trafficking [92].
An OASIS knockout study produced mice exhibiting delayed osteoblast
maturation, reduced bone density, and osteoblast cells with grossly dilated ER containing
extracellular matrix proteins (ECM) reminiscent to what is observed in osteosarcoma. It
was demonstrated that the majority of the genes like Runt-related transcription factor 2
(Runx2) and Transcription factor Sp7 (Osterix), which are required for osteoblast
differentiation were not affected by the knockout. However, both procollagen-I mouse
transcripts, Col1a1 and Col1a2 were significantly decreased by the loss of Creb3l1
suggesting transcription regulator roles for these genes. Additionally, overexpression of
active cyclic AMP-responsive element-binding protein 3-like protein 2
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(CREB3L2/BBF2H7), an OASIS family member that is typically highly expressed in
chondrocytes could not rescue the procollagen-I expression. However, while Creb3l1 has
been proven to positively regulate Col1a1/a2 expression it cannot be the sole factor
because during the OASIS knockout study it was noted that while collagen-I genes had
reduced transcription, expression was not completely eradicated [93].
As of today, there has not been much investigation into the regulation of COPII
gene transcription and most of what is known is linked to the CREB3 family members.
CREB3L1 was discovered to be a transcriptional regulator of COPII genes during
investigation of Drosophila cyclic AMP response element-binding protein A (CrebA). It
was found that while the CREB3L1 ortholog isn’t required for basal secretion levels that
CrebA targets genes selectively upregulating secretory pathway transcripts in tissue
experiencing a high secretory demand. The group then expanded the study to mammalian
non-secretory HeLa cells. Similarly, when they overexpressed CREB3L1 it resulted in
selective upregulation of genes encoding SAR1A, SEC23A, SEC24D, SEC24A, as well as
other COPII transcripts implicating CREB3L1 as a direct regulator of secretory capacity
[94]. Recently, patients have been identified to carry mutant CREB3L1 resulting in
osteogenesis imperfecta, a disease characterized by brittle bones due to lacking normal
type-1 collagen protein deposition in the bone matrix. Overexpression studies of the
CREB3L1 patient-derived mutants resulted in reduced expression of SEC23A and
SEC24D transcripts compared to wild-type, further corroborating CREB3L1 as a COPII
transcriptional regulator[95, 96].
CREB3L2/BBF2H7
Prior to the discovery of OASIS regulation of COPII genes, a family paralog,
CREB3L2/BBF2H7 was discovered to regulate subsets of COPII transcriptional
expression. It was initially discovered from a fusion protein identified in fibromyxoid
sarcoma as result of chromosomal translocation. As a CREB3 paralog it shares structural
homology with OASIS but has higher tissue-specific expression in chondrocytes that
secrete an abundance of type-II collagen protein. It is also an ER-membrane bound
transcription factor that requires COPII packaging for trafficking to the Golgi, where it
will be processed into an active transcription factor [88]. Similar to the phenotypes
observed in CREB3L1 knockout cells and OS patient tumor samples, in vivo knockout of
CREB3L2 resulted in disrupted secretion of extracellular matrix proteins and distended
ERs. These mice died shortly after birth, but it was also discovered that Sec23a
transcripts were significantly downregulated by about 80% in these mice. The knockout
cells were further used in overexpression studies of active CREB3L2 and were able to
rescue expression of Sec23a, while other COPII genes appeared unaffected by both the
initial loss and overexpression. They even demonstrated CREB3L2 to bind to the CRElike region of the promoter of Sec23a. Interestingly, they reported that overexpression of
active OASIS could not restore Sec23a expression in these cells, despite previous reports
of it to positively regulate SEC23A expression in HeLa cells [97]. Unlike other UPR
proteins it was found that ER stress only mildly increased transcription of CREB3L2, but
instead appeared to dramatically upregulate translation of the protein [98]. A knockout
study of medaka fish developmental revealed that in embryo the CREB3L2-KO medaka
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had significantly downregulated expression of sec23a, sec24d, sec13, sec31a, and tango1
transcripts, as well as other genes involved in COPII and ERGIC fusion compared to wild
type embryos. Additionally, the overexpression of active CREB3L2 in these embryos
enhanced transcription of this subset of COPII genes, corroborating evidence the protein
functions as a COPII gene regulator. Collagen-II transcripts were reported to be
significantly decreased and the type-II collagen that was transcribed was reportedly not
secreted but remained ER localized[99]. While there remains much to be discovered
surrounding COPII gene regulation especially in specialized tissue types, it is evident that
the UPR plays a critical role.
The genomic instability of pediatric osteosarcoma patients results in diversity
amongst patients. Therefore, our group decided to use the unusual ER phenotype, the one
characteristic that all patients exhibit, as a starting place. We hypothesized that
understating the root cause of the grossly dilated ER morphology would provide insights
into molecular signatures of the disease that are shared across the majority of patients.
Our long-range goal is to identify conserved molecular signature(s) or dysregulated
pathway(s) that might be exploited for much needed new treatment options. Therefore,
the first aim I aspired to accomplish was to determine the molecular cause of the dilated
ER morphology and the second aim was to understand how this morphology was
interconnected to tumorigenesis.
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CHAPTER 2. A NOVEL MOLECULAR SIGNATURE OF PEDIATRIC
OSTEOSARCOMA REVEALS THE CAUSE OF THE HALLMARK DILATED
ENDOPLASMIC RETICULUM MORPHOLOGY

Introduction
Osteosarcoma (OS) is a high-grade, malignant tumor of the bone that produces
osteoid tissue and is the most common pediatric bone tumor[100]. Primary disease most
often occurs at the metaphyses of the distal femur, proximal tibia, or proximal humerus
during periods of rapid growth in adolescents 10-19 years old. The exact cell origin of OS
remains unclear, with evidence supporting both mesenchymal stem cells, as well as
committed osteoblast precursors[1]. Histologically, OS tumors can be divided into
multiple subtypes and are classified according to the predominant type of stroma. The
most common are conventional OS tumors, of which osteoblastic tumors represent
approximately 70% of cases, while chondroblastic and fibroblastic tumors each represent
about 10%. However, there is no evidence for prognostic distinctions among these.
Much rarer subtypes of OS include telangiectatic, small-cell, and low-grade OS[2, 101].
It has been proposed that these different subtypes may arise from initial driver mutations
occurring in distinct cells along the osteoblast differentiation pathway, but this remains to
be proven. For all histological subtypes, the presence of osteoid is a requirement for the
diagnosis of OS[1, 2].
Collagen-I is a secreted protein that makes up ~94% of osteoid. It is synthesized
in the endoplasmic reticulum (ER) from the precursor procollagen, which is composed of
two COL1A1 and one COL1A2 polypeptide chains [102-104]. Normal mesenchymal to
osteoblast transition and bone formation are accompanied by activation of a cellular
stress pathway referred to as the unfolded protein response (UPR) that is regulated by
three ubiquitously expressed, up-stream signal transducers, IRE1, PERK and ATF6[87].
CREB3L1 is an additional osteoblast specific UPR transducer that is a member of the
ATF6 family, which functions as a transcription factor for COL1A1 expression[105].
Consistent with the other UPR transducers, CREB3L1, is dependent on ER stress for its
activation. The signal for activating the UPR during osteoblast differentiation involves
expression of BMP2, a TGFβ family member, although the process is complex and not
completely understood [106]. The procollagen chains enter the ER co-translationally
where they undergo multiple post-translational modifications and are assembled into rigid
helical trimers that are 300-400nm in length. Like all secretory pathway cargo, once the
procollagen trimers pass ER quality control measures that monitor their folding,
assembly, and post-translational modifications, they are packaged into coat protein
complex II (COPII) vesicles for anterograde transport to the Golgi apparatus [23, 107,
108].
OS is characterized by extreme chromosomal instability and gene copy number
variations, resulting in genetic heterogeneity across tumors and diversity among patient
tumors[11, 12, 109], and in fact is reported to have the highest somatic mutation
occurrence among pediatric cancers [110, 111]. This striking variability has prevented the
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identification of a conserved molecular etiology for OS. Instead, tumorigenesis appears
to be the result of several different driver mutations and aberrant signaling pathways that
synergistically combine to produce these aggressive and genetically complex tumors[13,
110-112]. While the majority of OS tumor incidence occurs sporadically, individuals
with certain cancer predispositions (i.e., Li-Fraumeni syndrome, hereditary retinoblastoma, Rothmund-Thomson syndrome, etc.) run a higher risk of incidence [11]. This
implicated both TP53 and RB1 in OS tumorigenesis, and in fact mutations of both are
common among all types of sporadic OS [13, 109, 111, 113]. The use of genetically
engineered mouse models and patient-derived xenograft (PDX) studies demonstrated the
ability of TP53 mutations to serve as a driver of OS. Molecular characterization of
patient tumors has also identified activation or increased expression of several oncogenes
including proto-oncogene c-Fos (C-FOS), transcription factor AP-1 (C-JUN) and MYC
proto-oncogene (C-MYC), as well as disruptions in a number of signaling pathways like
phosphoinositide-3-kinase (PI3K), Mitogen-activated protein kinase (MAPK), and
Receptor tyrosine-protein kinase erbB-4 (ERBB) in individual tumors arguing for their
contribution to OS tumorigenesis [13, 101, 114]. However, none of these alterations
occur at a sufficiently high rate to be considered a defining molecular signature for this
tumor.
The current treatment of OS is a combination of non-specific neoadjuvant
therapies and tumor-resection surgery, followed by administration of additional
chemotherapeutics. This regimen results in a 5-year survival rate of 65-70% for
individuals presenting with localized tumors, but only 0-29% for those with recurrent or
metastatic OS at the time of diagnosis [7, 115]. Unfortunately, there has been little
progress in the treatment or survival of patients with any form of OS over the last three
decades. Although whole genome sequencing of tumors has led to novel treatment
strategies for a number of cancers, the complex genetic characteristic of OS has
precluded the identification of conserved molecular vulnerabilities that might be so
leveraged.
Despite the genetic diversity among OS tumors, there is a single unifying feature
most consistently observed in all OS tumors examined by electron microscopy; the
presence of extremely dilated ER [14, 15, 116]. This ultrastructural abnormality is
unique to OS and is conserved in pediatric OS tumors and their corresponding PDXs, as
well as in the SaOS2 cell line that is commonly used in OS studies[117]. To understand
the significance of this aberrant phenotype to OS, we used a combination of RNA-seq
data derived from 108 patient tumors[118], PDXs and OS cell lines, coupled with
biochemical and cell biological assays. We identified a highly conserved decrease in the
expression of four critical COPII gene transcripts relative to that observed in normal
osteoblast tissue. This correlated with the retention of collagen-I within the ER and led to
the abnormal ER morphology that is characteristic of all OS tumors. Using the nuclease
deficient dCas9-SunTag-VP64 system[119], we found that restoration of only two of
these COPII proteins, SAR1A and SEC24D, to levels observed in normal osteoblasts,
was sufficient to restore collagen-I secretion and relieve the abnormal ER dilation. This
decrease in expression of a subset of COPII transcripts and proteins may represent the
first uniform molecular signature for pediatric of OS tumors.
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Materials and Methods

Cell culture
The hFOB1.19 cells were obtained from the American Type Culture Collection
(ATCC) and cultured at 34°C with 5% CO2 and grown in DMEM/F-12, no phenol red
(GibcoTM), supplemented with 10% fetal bovine serum and 1% L-glutamine.
Osteosarcoma cell lines SaOS2, U2OS, and 143B were gifts from Dr. Michael A. Dyer
(St. Jude Children’s Research Hospital), cultured at 37°C and 5% CO2 and grown in
Dulbecco’s modified Eagle medium(Corning™), supplemented with 10% fetal bovine
serum and 1% L-glutamine. 143B is additionally cultured in 0.015mg/ml 5-bromo-2'deoxyuridine (Sigma-Aldrich), per guidelines of ATCC.

Transmission electron microscopy
For ultrastructural analysis by EM, cells were seeded on tissue culture treated
dishes. Upon reaching a confluency of ~70% samples were fixed as monolayers in 0.1M
cacodylate buffer containing 2.5% glutaraldehyde and 2% paraformaldehyde then
scraped and pelleted for further processing. Samples were post-fixed in osmium
tetroxide and contrasted with uranyl acetate. Dehydration was by an ascending series of
ethanol to 100% followed by 100% propylene oxide. Samples were infiltrated with
EmBed-812 and polymerized at 80C. Samples were sectioned at ~70nm on a Leica
(Wetzlar, Germany) ultramicrotome, mounted on bare copper support grids and examined
in a ThermoFisher Scientific (Hillsboro, OR) TF20 transmission electron microscope.
Images were captured on an Advanced Microscopy Techniques camera system (Woburn,
MA). Unless otherwise stated, all reagents were sourced from Electron Microscopy
Sciences (Hatfield, PA).

ER area measurement
Transmission electron microscopy images were imported into ImageJ Software
and scale set based on image calibration. Using the Freehand Selection tool all
identifiable ER was traced. SaOS2 vs SaOS2.ST(+COPII), n= 4-5 individual cells per
cell line with 26-31 total ER regions measured. 143B.ST vs 143B.ST(+COL1), n=3-5
individual cells per cell line with 32 total ER regions measured each. ImageJ area
measurements were exported for statistical analyses to Prism Ver. 9 (GraphPad Software)
and analyzed by Student's t-test (unpaired; two-tailed).

RNA-sequencing
RNA-seq was performed by the Genome Sequencing Facility at St. Jude
Children’s Research Hospital. RNA was quantified using the Quant-iT RiboGreen assay
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(Life Technologies) and quality checked by 2100 Bioanalyzer RNA 6000 Nano assay
(Agilent,) 4200 TapeStation High Sensitivity RNA ScreenTape assay (Agilent,) or
LabChip RNA Pico Sensitivity assay (PerkinElmer) prior to library generation. Libraries
were prepared from total RNA with the TruSeq Stranded Total RNA Library Prep Kit
according to the manufacturer’s instructions (Illumina, PN 20020599). Libraries were
analyzed for insert size distribution on a 2100 BioAnalyzer High Sensitivity kit (Agilent
Technologies,) 4200 TapeStation D1000 ScreenTape assay (Agilent Technologies,) or
Caliper LabChip GX DNA High Sensitivity Reagent Kit (PerkinElmer.) Libraries were
quantified using the Quant-iT PicoGreen ds DNA assay (Life Technologies) or low pass
sequencing with a MiSeq nano kit (Illumina.) Paired end 100 cycle sequencing was
performed on a HiSeq 4000 (Illumina.).

UPR induction
Cells were seeded 24h prior and upon achieving ~70% confluency were treated
with a final concentration of 1uM Thapsigargin (Sigma-Aldrich) by addition to the cell
medium. Cells were harvested at the indicated time points, washed 2x with PBS and cell
pellets preserved at -20°C until further sample processing.

Reverse transcription PCR
Total RNA was isolated using the RNeasy Kit (Qiagen) and was reverse
transcribed using the SuperScript™ III Reverse Transcriptase (Invitrogen). PCR
amplification and analysis were performed using 0.5-1ug of cDNA with AmpliTaq™
DNA Polymerase with Buffer II (Applied Biosystems) and 10uM of primer pairs
XBP1.UandS and GAPDH primer pairs, listed in (Table A-1) Amplified PCR products
were separated on 2% agarose gel (Sigma-Aldrich).

Immunoblotting
Cells were washed twice with PBS and lysed on ice in NP40 lysis buffer (50mM
Tris pH 7.5, 150mM NaCl, 0.5% NP-40, 0.5% deoxycholic acid), 0.1 mM PMSF and a
protease inhibitor cocktail. Lysates were clarified by a centrifugation of 21,000g for 15m
at 4°C. In all cases, prepared samples were resolved under reducing conditions on SDSPAGE gels ranging from 7% to 12% and transferred to PVDF membranes. Antibodies
used for immunoblotting were anti-GRP170[120], anti-human BiP, kindly provided by
Ineke Braakman (Utrecht University, Utrecht, Netherlands), anti-CHOP[121], antiHSC70 (Santa Cruz #sc-7298), anti-SAR1A (Santa Cruz #sc-130463), anti-SEC24D
(Cell Signaling #14687s), anti-GAPDH (Milipore #MAB374) and anti-SP1.D8 (DSHB
#SP1.D8). SP1.D8 was deposited to the DSHB by Furthmayr, H. (DSHB Hybridoma
Product SP1.D8).
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DNA transfection with metabolic labeled immunoprecipitation
SaOS2 cells were seeded 24h prior to transfection, which was performed using
GeneCellin HTC (Bulldog Bio) according to the manufacturer's protocol. For analysis of
the effects of restored SAR1A and SEC24D on collagen-I secretion, cells received either
transfection reagent alone or 1ug of each construct individually or in combination,
SAR1A (Addgene plasmid #67472), SEC24D (Addgene plasmid #32677). ~48h posttransfection cells were labeled 16hrs, with 0.1mCi of Express [35S] Labeling Mix
(PerkinElmer) in DMEM labeling media without Met/Cys (Corning), supplemented with
10% dialyzed fetal bovine serum and 1% L-glutamine. Media was harvested and
centrifuged at 500 g for 5mins to pellet any unattached cells. Supernatant was transferred
to a tube with final concentration of 50mM Tris-HCl pH 7.5, 150mM NaCl, and 0.5ug of
anti-SP1.D8 (DSHB).
Cells were washed twice with PBS and lysed in NP-40 lysis buffer on ice for 20
minutes. Lysates were clarified by centrifugation at 21,000 g for 15 minutes and 0.5ug
anti-SP1.D8 (DSHB) was added to the clarified lysates. All samples were incubated at
4°C overnight while rotating. Protein A agarose was then added for 1hr, and isolated
immunoprecipitated complexes were analyzed by SDS-PAGE under reducing conditions,
gel was dried at 80°C and exposed to BioMax MS Film (Kodak).

Metabolic labeling and immunoprecipitation
Cells were seeded at a density of 1x106 on 60mm dish and left to adhere for a few
hours. The dishes were washed 2x with PBS to remove any medium. Cells were labeled
16hrs, overnight with 0.1mCi of Express [35S] Labeling Mix (PerkinElmer) in DMEM
labeling media without Met/Cys (Corning), supplemented with 1% dialyzed fetal bovine
serum and 1% L-glutamine.
Media was harvested and centrifuged at 500 g for 5m to pellet any unattached
cells. Supernatant was transferred to a tube with a final concentration of 50mM Tris-HCl
pH 7.5, 150mM NaCl and either, anti-Collagen I (Abcam #ab34710) or anti-[COL-1]
(Abcam #ab90395). Note: Due to the discontinued production of anti-[COL-1] #ab90395,
anti-Collagen I #ab34710 was used in later sets of experiments. Figure legends indicate
specific antibody used.
Cells were washed twice with PBS and lysed in NP-40 lysis buffer on ice for 20
minutes. Lysates were clarified by centrifugation at 21,000 g for 15m and antiProcollagen-I antibodies, anti-SP1.D8 (DSHB) or anti-M-38 (DSHB) were added to the
lysates. Antibody used is indicated in figure legend. All samples were incubated at 4°C
overnight while rotating. Protein A agarose was then added for 1hr, and isolated
immunoprecipitated complexes were analyzed by SDS-PAGE under reducing conditions.
A Hyphoon FLA 9500 phosphorimager (GE Healthcare, Pittsburgh, PA) was used to
detect signals, which were analyzed with the ImageQuant TL software (GE Healthcare,
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Pittsburgh, PA). anti-M-38 was deposited to the DSHB by McDonald, J.A. (DSHB
Hybridoma Product M-38).

Plasmid construction
Plasmid constructs are listed in (Table A-2) Perturb-seq gRNA vector backbone,
pBA439 (Addgene plasmid #85967) was modified by restriction enzyme (RE) digest at
NheI and EcoRI sites to remove the puromycin-T2A-TagBFP fragment. In-Fusion HD
cloning (Takara) was used to insert a puromycin-T2A-mCherry amplified fragment
generating pBA439_puro.mCherry backbone. Additionally, the NheI/EcoRI digested
pBA439 backbone was used in combination with Gibson Assembly to insert a neomycin
resistance fragment and a T2A-mCherry fragment generating pBA439_Neo.mCherry
backbone.
The two-guide expression vectors (pMJ114, Addgene plasmid #85995 and
pMJ179, Addgene plasmid #85996) were RE digested and gRNAs inserted as previously
described by (Adamson et al., 2016). Next, these expression plasmids were PCR
amplified at regions flanking the sgRNA expression cassettes. SaoS2 COPII gene
targeting sgRNA cassettes were Gibson assembled into pBA439_puro.mCherry backbone
and 143B collagen-I targeting sgRNA cassettes were Gibson assembled into the
pBA439_Neo.mCherry backbone at XhoI/HpaI RE sites. sgRNA sequences are listed in
(Table A-3). Last, pHIV-Luc-ZsGreen (Addgene plasmid #39196) was modified by RE
digest at ClaI/BstXI sites to remove ZsGreen. A PCR-amplified YFP fragment was InFusion HD cloned (Takara) in place of ZsGreen generating a pHIV-Luc-YFP plasmid.

Viral production and cell line construction
Lentivirus was produced by calcium phosphate transfection of HEK293T cells
with standard 3rd generation packaging plasmids combined with the different transfer
plasmids. Viral media was harvested ~48h post-transfection and passed through a
0.45uM PDVF filter(Millipore). SaOS2 and 143B cells were stably transduced with
pHRdSV40-dCas9-10xGCN4_v4-P2A-BFP (Addgene plasmid #60903) and pHRdSV40scFv-GCN4-sfGFP-VP64-GB1-NLS (Addgene plasmid #60904) and bulk culture cell
sorted for a dual BFP/GFP(+) fluorescence population on a BD Biosciences Aria. The
suntag system integrated lines are hereby referred to as SaOS2.ST and 143B.ST.
Following, SaOS2.ST cells was stably transduced with pBA439.bU6.SEC24D.g2mU6.SAR1A.g28 viral media. 48h post-transduction cells were placed in a 2ug/mL
puromycin selection (InvivoGen) for a minimum of five days to select for
SaOS2.ST(+COPII) cells. Similarly, 143B.ST cells were stably transduced with
pBA439.bU6.COL1A1.g1_mU6.COL1A2.g35 viral media and 48h post-transduction
were placed in a 1ug/mL G418 geneticin (InvivoGen) for a minimum of five days to
select for 143B.ST(+COL1) cells. Both the sgRNA expression cell lines were stably
transduced with pHIV-Luc-YFP viral media and subjected to bulk culture cell sort of a
BFP/GFP/mCherry/YFP(+) population on a BD Biosciences Aria. Additionally, the
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parental non-sgRNA expressing lines, SaOS2.ST and 143B.ST were also stably
transduced with pHIV-Luc-YFP viral media and bulk culture cell sorted on a BD
Biosciences Aria for a BFP/GFP/YFP(+) population.

Real-time PCR
Total RNA was isolated using the RNeasy Kit (Qiagen) from cell pellets. RNA
was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems) and subjected to SYBR® Green chemistry-based qPCR according
to the manufacturer's protocol using the QuantStudio 3 Real-time PCR System (Applied
Biosystems). Primer pairs were obtained from (ThermoFisher Scientific) and sequences
are listed in (Table A-1). Relative mRNA fold change was computed from the
QuantStudio-generated Ct values by using the 2−ΔΔCt method. hFOB1.19 mRNA levels
were normalized to 1, and OS cells mRNA levels were plotted as a relative measure of
hFOB1.19 levels. Statistical analyses were performed using Prism Ver. 9 (GraphPad
Software) by Student's t-test (unpaired; two-tailed).

Super- resolution structured illumination microscopy
SIM (Structured Illumination Microscopy) images were collected with a Zeiss
ELYRA PS.1 super resolution microscope (Carl Zeiss MicroImaging) using a 63x oil
objective lens with 1.4 NA at room temperature. Three orientation angles of the
excitation grid were acquired for each Z plane, with Z spacing of 110 nm between planes.
SIM processing was performed with the SIM analysis module of the Zen 2012 BLACK
software (Carl Zeiss MicroImaging). A three-dimensional reconstruction of SIM data was
created using the MARIS software (Bitplane) and exported as tiff images.

Results

Ultrastructure of pediatric osteosarcoma
A number of OS patient-derived xenografts (PDX) tumors have been established
at SJCRH that were available for our studies[16]. When these PDXs were grown in mice
using an orthotopic model, we found that the isolated tumors also possessed the grossly
dilated ER phenotype that is characteristic of OS primary tumor samples (Figure 2-1A,
B). However, these PDXs have not been adapted to tissue culture, thus limiting the
biochemical and cell biological assays available to characterize the ER defect. Therefore,
to begin with a more experimentally tractable system that could be used to guide subsequent studies with PDX and patient tumors, we obtained three OS cell lines that are
commonly used in studies and a pre-osteoblast cell line, as a control. Examination of
these lines using transmission electron microscopy revealed that the osteoblast line
hFOB1.19 possessed a normal ER morphology (Figure 2-1C), which is similar to that
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Figure 2-1.
lines.

EM analysis of OS PDX tumors, pre-osteoblast, and osteosarcoma cell

(A,B) Electron microscopy images of osteosarcoma xenografts derived from two
different patient tumors exhibited the same dilated ER phenotype [indicated by arrows] as
has been observed in primary tumors. The cell lines chosen for an initial experimental
model consist of a control osteoblast cell line (C) hFOB1.19 possessing a normal ER, the
OS cell line (D) SaOS2 with dilated ER [white arrows], as well as (E) U2OS and (F)
143B, two OS lines that exhibit normal ER morphology [indicated by arrows].

25

observed in healthy osteoblast tissue. This demonstrated that the abundant production of
collagen by osteoblasts does not distort the ER but instead shows that the abnormal ER
phenotype is specific to malignant osteosarcoma cells. Examination of the OS cell lines
revealed that only the SaOS2 line exhibited the dilated ER morphology characteristic of
OS patient tumors and PDXs (Figure 2-1D). While the U2OS and 143B OS cell lines had
very little detectable ER, it appeared normal in both cell lines (Figure 2-1E, F) This
revealed that the phenotype is not specific to the transformation process, at least in
cultured cells, as both of these OS lines are widely used in xenograft studies[117] and the
143B line is a model for metastatic disease[122].

The dilated ER phenotype associated with OS is not due abnormal UPR activation
The UPR is known to play an essential role in osteoblast differentiation[105], and
it is activated in many solid tumors[123-126] and tumor cells lines[123, 126, 127]
compared to appropriate controls. We explored whether the dilated ER indicated a more
robust ER stress response in the OS cell lines and PDX tumors. RNA-seq analysis was
completed on two OS-PDXs; SJOS001132 and SJOS001121, which was compared to
human osteoblast tissue, and the three OS cell lines; SaOS2, U2OS, and 143B, as well as
a pre-osteoblast cell line, hFOB1.19, which served as the control for these OS lines.
Transcript levels of UPR targets downstream of each of the three transducers were
examined to determine if the OS tumors or lines were experiencing more severe ER stress
compared to normal osteoblasts and cell lines. We found that none of the three UPR
branches were activated beyond levels observed in the appropriate control osteoblast
tissue, and some targets were actually expressed at much lower levels (Figure 2-2A).
Furthermore, RNA expression data obtained from the 108 pediatric OS patient tumors
were extracted from the Pediatric Cancer (PeCan) database and normalized to normal
human osteoblast tissue. Consistent with the PDX tumors, data from primary tumors
similarly revealed downstream UPR target transcripts were expressed at similar or lower
levels in tumors than those observed in non-transformed osteoblasts (Figure 2-2B). One
PDX tumor had a modest increase in GRP170 transcripts, as did a primary tumor. It is
noteworthy that GRP170 is also an oxygen-regulated gene known as ORP150, which is
up-regulated by hypoxic conditions [128]. The fact that other ATF6 targets were not
increased in this PDX or patient tumor argues that the increase in GRP170 is not
indicative of enhanced UPR activation.
We hypothesized that the expression of UPR target genes observed in the OS
tumors already represented maximal activation of this response in this tissue, which is
known to be a component of osteoblast differentiation. To test this possibility, OS cell
lines 143B, SaOS2, and U2OS were treated with thapsigargin, a chemical ER stress
inducer, and harvested at two timepoints. RT-PCR analysis of the OS lines demonstrated
a significant increase in the spliced form XBP-1s, indicating activation of the IRE1
branch of the UPR signaling cascade (Figure 2-2C). Analysis of the effects of
thapsigargin on expression of UPR target proteins revealed a modest up-regulation of BiP
and a robust increase of CHOP levels, demonstrating the ability of both the ATF6 and
PERK transducers to also respond further to ER stress (Figure 2-2D). We were unable to
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Figure 2-2. OS tumors display a low level of UPR activation that is comparable to
normal controls, but OS lines retain the ability to respond robustly to
pharmacological inducers.
(A) RNA-Seq analyses revealed downstream UPR transcripts were expressed either at
comparable or lower levels than that of normal osteoblast controls. Data consist of two
SJCRH PDXs (solid bars) normalized to normal human osteoblast tissue, n=2 and three
OS cell lines (striped bars), normalized to hFOB1.19, n=3. (B) The box and whiskers plot
display the interquartile range of log2 fold change from UPR targets of 108 OS patient
tumor samples. The midline bar plots the median of the group. PeCan data is normalized
to human osteoblast tissue, n=2. (C) 24hrs after seeding, OS lines SaOS2, U2OS, 143B
were subjected to 1 M thapsigargin (Tg) treatment for the indicated timepoints. Total
RNA was extracted, reverse transcribed and analyzed by RT-PCR for XBP1 transcripts.
PCR products were separated on a 3% agarose gel. GAPDH was provided as a loading
control. (D)After treatment samples were lysed in NP40 buffer and analyzed for UPR
induction via SDS-PAGE probing. HSC70 was provided as a loading control.
Immunoblots were developed by chemiluminescence on film. ns> 0.05, *P≤0.05,
**P≤0.01 and ***P≤0.001.
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examine the ability of the PDX lines to respond to an ER stressor, as they do not grow
ex-vivo. In summary, these data do not indicate that excessive UPR activation is present
in OS tumors or cell lines, and therefore was not the cause of their dilated ER.

Procollagen I accumulated within dilated ER
The EM data (Figure 2-1) revealed electron dense material within the dilated ER
of OS cells that was consistent with the accumulation of protein. One of the most highly
synthesized proteins in osteoblasts and OS cells is type I collagen, which makes up the
majority of the osteoid matrix. We compared the log2 value of the mean RNA expression
for collagen-I transcripts, COL1A1 and COL1A2, collected from RNA-seq data. Normal
human osteoblast tissue and both OS-PDXs had equivalent levels of the two collagen-I
transcripts (Figure 2-3A). This demonstrated that unusually high levels of collagen
expression was not the cause of ER dilation in OS tumors, and that osteoblasts are wellsuited to accommodate the high secretory demands associated with this unusual protein.
The osteoblast cell line, hFOB1.19 and OS line SaOS2, which possessed the dilated ER
phenotype, made similar levels of the two collagen-I transcripts, albeit at much lower
levels than the PDX tumor samples. Intriguingly, the U2OS and 143B OS lines with a
normal ER produced very low amounts of the COL1A1 and COL1A2 transcripts (Figure
2-3A). Analysis of the collagen-I expression data available from the PeCan database
revealed that the majority of 108 OS tumors expressed the COL1A1/A2 transcripts at
levels equivalent to normal osteoblast tissue (Figure A-1). This indicates that lack of
collagen-I genes transcription in the U2OS and 143B lines is unusual for OS tumors.
Although the hFOB1.19 osteoblast and SaOS2 tumor line produced equivalent
collagen-I transcript levels (Figure 2-3A), examination of corresponding cell lysates
revealed much higher levels of procollagen-I in SaOS2 cells (Figure 2-3B). In keeping
with the RNA expression data, procollagen-I protein was only weakly expressed in U2OS
cells and undetectable in 143B cells (Figure 2-3A). To establish if there was a defect in
protein secretion from the OS cells, we metabolically labeled the hFOB1.19 and SaOS2
cell lines and immunoprecipitated collagen-I from both the cell lysates and culture media.
Our data revealed that although both lines produced type I procollagen at similar
levels, the osteoblast line readily secreted it, whereas procollagen produced in SaOS2
cells remained largely cell associated (Figure 2-3C). Analysis of the SaOS2 cell line
using super-resolution structured illumination microscopy revealed the procollagen-I
accumulation within globular shaped ER of SaOS2 cells, compared to hFOB1.19 cells,
where procollagen was also observed outside the ER having trafficked further along the
secretory pathway (Figure 2-3D). Together this indicates that the defect in procollagen-I
secretion is due to abnormal ER retention, which contributes to the electron dense
material observed within the dilated ER of OS. Furthermore, the lack of ER dilation in
the U2OS and 143B OS lines is likely due to the absence of collagen production.
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Figure 2-3.

Accumulation of procollagen-I in SaOS2 cells.

(A) The heatmap is a representation of the log2 value of averaged FPKM reads acquired
from RNA-seq analyses for COL1A1 and COL1A2 transcripts. Above the graph, each
sample is annotated for either a (-/+) dilated ER morphology. (B) SDS-PAGE analysis of
cell lines probed for collagen-I (anti-SP1.D8). HSC70 was provided as a loading control.
(C) Cell lines were metabolically labeled, conditioned media harvested, and cells lysed in
NP40 buffer. Both lysate and media were immunoprecipitated with anti-SP1.D8 serum
and analyzed by reduced SDS-PAGE. (D) Super-resolution structured illumination
microscopy of hFOB1.19 and SaOS2 revealed an abundance of procollagen-I within the
ER of SaOS2 relative to hFOB1.19 osteoblasts. The cells were stained for the nucleus
with DAPI (blue), ER luminal protein GRP170 (green) and procollagen-I (anti-SP1.D8,
red), the (yellow) is an overlay of procollagen-I within the ER.
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Decreased expression of a subset of COPII transcripts in OS tumors and cell lines
The absence of robust UPR activation and up-regulation of ER chaperones
indicated that the defect in collagen secretion was unlikely to represent a problem with
collagenfolding or assembly in the ER. Once secretory cargo has matured properly and
passed ER quality control measures, it is transported from the ER to the Golgi in COPII
vesicles. The formation of these vesicles at ER exit sites is initiated when the GTPbound form of SAR1 inserts into the cytosolic leaflet of the ER membrane, which is
followed by the assembly of an inner coat composed of SEC23:SEC24 heterodimers and
an outer coat of SEC13:SEC31 heterodimers. This process results in the budding of
vesicles with defined geometries measuring 60-80nM in diameter that contain secretory
cargo. Although, the rigid procollagen trimers that assemble in the ER are ~ 300-400nM
in length, they are still transported to the Golgi in COPII vesicles. This requires two
additional specialized proteins, TANGO1 and cTAGE5, that bind procollagen at ER exit
sites and assist the distortion of the COPII geometry to form mega-carrier vesicles[38,
108, 129]. To determine if cargo recognition or vesicle assembly was defective, we
examined transcript levels of the 22 possible proteins involved in the formation of COPII
vesicles for transporting procollagen. We found that TANGO1 and cTAGE5 transcripts
were expressed at normal levels in the OS lines, PDX tumors, and patient tumors
compared to the appropriate controls (Table A-4). Thus, neither recognition of the
procollagen triple helices for packaging nor the ability to alter the COPII vesicles to
accommodate this rigid cargo appeared to be defective.
We also examined the expression of the multiple isoforms corresponding to
conventional proteins of COPII vesicles. RNA-seq data obtained from the two OS-PDXs
and three OS cell lines normalized to their control tissues revealed that mRNA levels for
most components were very similar to that found in their respective normal controls.
However, there was a significant decrease in expression of six COPII genes; SAR1A,
SAR1B, SEC23A, SEC23B, SEC24A, and SEC24D in most of these (Figure 2-4A). To
determine if the trend we observed in our PDX and OS cell lines was representative of
patient tumors, we compared RNA expression data that was available for 108 pediatric
OS patients in the PeCan database to human osteoblast tissue. This analysis revealed
patient tumors showed decreased expression of four of these six COPII components
(Figure 2-4B). These included a fold change of SAR1A (avg. log2 -1.5), SEC23A (avg.
log2 -1.3), SEC24A (avg. log2 -1.2) and SEC24D (avg. log2 -0.8). Similar to the OS cell
lines and PDXs, the remaining 18 COPII genes were largely unchanged. These data
suggested that a defect in inner-coat assembly could be a possible cause for the abnormal
ER phenotype that is a hallmark of OS tumors and revealed for the first time a molecular
signature encompassing the majority of OS tumors despite the intra- and inter-tumor
genetic heterogeneity associated with this tumor type.

Producing CRISPR-dCas9 modified SaOS2 cells to restore COPII expression
A previous study employed siRNA to reduce the expression of 18 of the COPII
components in order to identify which ones were required to transport procollagen-I.
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Figure 2-4.

COPII transcripts are decreased in OS patients, PDXs and cell lines.

(A) RNA-Seq analyses of COPII transcripts consist of two SJCRH PDXs (solid bars)
normalized to normal human osteoblast tissue, n=2 and three OS cell lines (striped bars),
normalized to hFOB1.19, n=3. (B) The scatter plot displays the log2 fold change of
COPII transcripts from 108 OS patient tumor samples. The (black) midline bar plots the
mean of the group. The PeCan RNA expression data was normalized to human osteoblast
tissue, n=2. *P≤0.05, **P≤0.01, ***P≤0.001 and ****P≤0.0001.
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They found only 8 of these proteins were critical for collagen-I secretion [48]. SAR1A
and SEC24D were among those that were required, whereas decreased expression of
SEC23A or SEC24A did not affect collagen secretion. This suggested to us that restoring
the expression of only two proteins might be sufficient to both rescue collagen secretion
and establish normal ER morphology. To assess if this might be the case, we transiently
expressed SAR1A and SEC24D constructs in the SaOS2 cell line and observed an
increase in collagen-I secretion (Figure A-2).Therefore, to determine which methods
might be amenable to stable restoration of SAR1A and SEC24D expression, we exploited
the fact that in-depth, genome-wide transcriptional analyses were available on pediatric
OS-PDX [16] tumors and found that epigenetic silencing was not responsible for the
reduction in COPII transcript levels (Figure A-3A, B). Since both the SAR1A and
SEC24D genes were transcriptionally active, we chose the nuclease deficient dCas9SunTag-VP64 system [119] to restore their expression from their endogenous promoters.
This multi-component system uses an enzymatically inactive Cas9 protein (dCas9) that is
fused with a 10x peptide repeat, which acts as an antigen to recruit intrabody proteins
fused to strong transcriptional activator, VP64. The SaOS2 cells were transduced with
lentiviruses containing these various SunTag components to obtain a control line
SaOS2.ST, which would also be used to introduce single guide RNAs (sgRNAs). We
designed ten gRNAs to target each of the promoter regions of SAR1A and SEC24D and
tested independently for their ability to increase the expression of these proteins to a level
as close as possible to that observed in the osteoblast cell line, hFOB1.19. Based on this
criteria, one gRNA was chosen for each gene and engineered into the dual sgRNA
expression cassette. Stable bulk cell lines were selected for puromycin resistance, which
we referred to as SaOS2.ST(+COPII) (Figure A-4).
Examination of the SaOS2.ST(+COPII) cells revealed SAR1A and SEC24D
transcript and protein levels were restored to levels similar to those observed in the
normal bone cell line, hFOB1.19 (Figure 2-5A, B). To determine the effect of restoring
these two COPII proteins on collagen-I secretion, the SaOS2.ST and SaOS2.ST(+COPII)
cells were metabolically labeled and both culture media and cell lysates harvested and
immunoprecipitated for either procollagen-I or secreted collagen-I protein. Significant
amounts of large collagen trimers were readily isolated from the media of the
SaOS2.ST(+COPII) cells compared to that observed with the parental SaOS2.ST cells,
indicating that restoring only SAR1A and SEC24D transcripts was sufficient to increase
collagen-I protein secretion from the ER (Figure 2-5C). Both cell lines were additionally
subjected to electron micrography, and ImageJ software was used to quantify ER area.
Relative to cells without sgRNA expression, SaOS2.ST(+COPII) cells displayed a
significant reduction in ER area (Figure 2-5D). Together, these data demonstrate that
decreased COPII protein resulted in ER retention of collagen-I protein and caused a gross
dilation of this organelle. Restoring levels of SAR1A and SEC24D protein led to
increased collagen-I secretion and normalization of the dilated ER morphology associated
with OS.
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Figure 2-5. Restoring SAR1A and SEC24D repairs collagen secretion and
subsequently ER morphology.
(A,B) SaOS2.ST cells were lentiviral transduced and selected for stable integration of
dual gRNA expression. qRT-PCR analysis of SAR1A and SEC24D mRNA transcripts
were normalized relative to hFOB1.19 cells, n=3. SDS-PAGE analysis of hFOB1.19,
SaOS2, and SaOS2.ST(-/+) gRNA expression lysates were probed for SAR1A and
SEC24D protein. GAPDH or HSC70 were provided as a loading control. (C) Cells were
35S labeled, conditioned media harvested, and cells lysed in NP40 buffer. Lysates were
immunoprecipitated for procollagen-I (anti-M-38) and media was immunoprecipitated for
collagen-I (anti-collagen I #ab34710) and analyzed by reduced SDS-PAGE. Experiment
repeated n=3. (D) Cells were subjected to electron microscopy and images analyzed in
Image J software. ERs were traced and measured based on image calibration, n= 4-5
individual cells per cell line with 26-31 total ER regions measured each. Statistical
differences of the assays were computed using unpaired, two-tailed Student’s t-tests, and
are indicated as *P≤0.05, **P≤0.01, ***P≤0.001 and ****P≤0.0001. Error bars indicate
mean ± SD.
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Collagen-I expression and decreased COPII transcripts results in ER dilation
The 143B OS cell line also had reduced SAR1A levels similar to those observed in
SaOS2 cells and even lower levels of SEC24D transcripts and protein (Figure 2-6A, B),
although their ER morphology was normal. However, 143B cells were unique because
they did not produce collagen-I unlike SaOS2, the PDXs and the 108 patient tumor
samples (Figure 2-3A and 2-1F). Therefore, to demonstrate that ER dilation is caused by
a combination of both normal collagen-I expression and a decrease in COPII transcripts,
we first introduced the dCas9-SunTag-VP64 system into these cells, which are hereby
referred to as 143B.ST cells. Next, sgRNAs targeting the COL1A1 and COL1A2
promoters were selected based on their ability to establish transcripts levels similar to that
of normal bone cell line hFOB1.19. The COL1A1 and COL1A2 sgRNA expressing cells
are referred to as 143B(+COL1) and a bulk culture was obtained, and COL1A1 and
COL1A2 transcripts were found to be very similar to those in the hFOB1.19 line (Figure
2-6C). When steady-state protein levels were detected by western blot, we found that
procollagen levels were actually somewhat greater in the 143B.ST(+COL1) compared to
the normal osteoblast line, which was reminiscent of the increased amount of collagen-I
expression in the parental SaOS2 cells compare to that in the hFOB1.19 osteoblast line
(Figure 2-3B, 2-6D). To determine if this might represent a defect in the ability to secrete
collagen-I, the 143B.ST and 143B.ST(+COL1) cells with were metabolically labeled, cell
lysates and culture media and cell lysates harvested, and immunoprecipitated for
procollagen-I and collagen-I secretion, respectively (Figure 2-6E). Although
procollagen-I was readily detected in the cell lysate of the cells expressing the sgRNAs
specific to COL1A1 and COL1A2, there was no evidence that collagen-I was being
secreted from these cells in the absence of normal COPII levels. To address the question
that initiated this study, we examined the effect of collagen-I expression on the ER
morphology of 143B.ST(+COL1) cells. Electron micrographs were obtained from the
143B.ST and 143B.ST(+COL1) cells, and the ER area was quantified using ImageJ
software. Images revealed that the collagen-I expressing 143B cells now contained a
significantly distended ER morphology that was consistent with that associated with OS
patient tumors (Figure 2-6F). In summary, from these data we can conclude that the
abnormal ER morphology that has been the single conserved feature of OS is due to the
reduced expression of a subset of COPII proteins in the face of normal collagen-I
expression. This causes collagen-I retention within the ER and results in the abnormal
ER dilation. To our knowledge, this subset of decreased COPII complex genes represents
the first conserved molecular signature for osteosarcomas.

Discussion
Approximately 1/3 of the coding sequences in the human genome provide
instructions for synthesizing proteins that enter the ER lumen where they undergo a
variety of post-translational modifications, fold, and often assemble into multimeric
complexes. Except for resident ER proteins, the remainder of these nascent proteins will
be transported to the Golgi through COPII transport vesicles, after they pass ER quality
control measures, regardless of their size or structural rigidity. In the past several years
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Figure 2-6. The combination of decreased COPII proteins and normal collagen-I
expression results in ER dilation in OS line 143B.
(A,B) qRT-PCR data of 143B.ST SAR1A and SEC24D mRNA transcripts were
normalized relative to hFOB1.19 cells, n=3. SDS-PAGE analysis of hFOB1.19 and
143B.ST lysates were probed for SAR1A and SEC24D protein. GAPDH was provided
as a loading control. (C) 143B.ST cells were lentiviral transduced and selected for stable
integration of a dual COL1A1 and COL1A2 gRNA expressing plasmid. qRT-PCR results
of 143B.ST and 143B.ST(+COL1) transcripts are normalized to hFOB1.19, n=3. (D)
SDS-PAGE analysis of hFOB1.19 and 143B.ST cells (-/+) gRNAs were probed from
pro-collagen I (anti-SP1.D8). HSC70 was provided as a loading control. (E) Cells were
35S labeled, conditioned media harvested, and cells lysed in NP40 buffer. Lysates were
immunoprecipitated for procollagen-I (anti-M-38) and media was immunoprecipitated for
collagen-I (anti-[COL1] #ab90395) and analyzed by reduced SDS-PAGE. Experiment
repeated n=3. (Electron microscopy images of 143B.ST cells (-/+) collagen gRNA
expression were analyzed in Image. Statistical differences of the assays were computed
using unpaired, two-tailed Student’s t-tests, and are indicated as *P≤0.05, ***P≤0.001
and ****P≤0.0001. Error bars indicate mean ± SD.
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significant progress has been made in our understanding of specificity among the various
COPII components and the mechanisms of assembling the mega-COPII vesicles required
for transporting large, rigid clients like collagen. Although traditional COPII components
are used, two additional proteins, TANGO1 and cTAGE5 are required to both recruit
proteins like collagen and alter the geometry of the vesicles[42]. The first step in
assembling all types of COPII vesicles involves SAR1, a small GTPase. In the GTPbound form, it inserts into the outer leaflet of the ER membrane through an N-terminal
helix at ER exit sites. The use of SAR1 hydrolysis mutants and non-hydrolysable GTP
analogues in cryo-EM studies indicated that slow GTP hydrolysis was critical to the
formation of larger, tubular carriers as opposed to standard spherical vesicles[34, 46]. In
keeping with this, the TANGO1/cTAGE5 complex interacts with both the GEF (SEC12)
and the GAP (SEC23) for SAR1 respectively, providing a mechanism to regulate the rate
of GTP hydrolysis during the formation of these larger vesicles [46, 130, 131]. There are
two very closely related isoforms of SAR1, but previous studies demonstrate that SAR1A
is required for collagen-I transport [47, 48].
The next step in COPII assembly is the recruitment of SEC23/SEC24
heterodimers by the GTP-bound form of SAR1. Although two isoforms of SEC23 exist,
autosomal recessive mutations in SEC23A were found to cause cranio-lenticulo-sutural
dysplasia, a disorder characterized by facial dysmorphism, late-closing fontanels, and
skeletal defects[132]. SEC23A mutant fibroblasts exhibit grossly dilated ER that
contained an abundance of procollagen-I protein and diffuse SEC31 patterns suggesting
defects in COPII vesicle formation [133]. Although SEC23A was one of the most downregulated transcripts in our dataset, we found that re-establishing levels of only SAR1A
and SEC24D were sufficient to restore collagen secretion and normal ER morphology.
Thus, it appears that the effects of mutant SEC23A were more severe than reduced levels
of this COPII component. There are four SEC24 isoforms present in mammals, which
are responsible either directly or indirectly through association with adaptor proteins for
cargo recruitment into assembling COPII vesicles[32]. The various isoforms of COPII
genes are thought to have evolved to handle the diverse cargo produced in different
tissues. Mutation of SEC24D have been identified that cause a rare autosomal recessive
form of osteogenesis imperfecta, a disorder characterized by skeletal fragility and
deformity due to reduced bone mass[134, 135]. Mapping these mutations onto the
SEC24D structure revealed that one occurs in the client recognition pocket and another in
the region that associates with SEC31 [134]. In keeping with this, SEC24D mutants
prevent procollagen export, which accumulates within dilated ER cisternae, reminiscent
of what is observed in OS tumor cells, our study, and in cranio-lenticulo-sutural
dysplasia. TANGO1 interacts directly with multiple SEC23 heterodimers resulting in the
formation of a helical lattice of SEC23/SEC24-SAR1, which assembles into a closely
packed structure that is compatible with the formation of large tubular-shaped buds, as
opposed to traditional spherical vesicles [42]. For both types of transport carriers, the
outer coat heterodimers composed of SEC13/SEC31 are added next. In conventional
COPII vesicles, they bind to the inner coat heterodimers in an approximately 1:1 ratio
and provide the cage-like geometry associated with these transport vesicles [136].
However, due to the closely packed structure of the inner coat of the larger tubular
carriers, the ratio of inner coat:outer coat proteins is about 2:1 [42]. So, in addition to
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requiring large amounts of COPII components, the tubular carriers that transport proteins
like collagen, require particularly abundant amounts of SAR1, SEC23, and SEC24
protein. Our study demonstrated that the four COPII components that are downregulated
in 108 pediatric OS tumors, PDXs, and OS cell lines included SAR1A, SEC23A,
SEC24A, and SEC24D. So, the very proteins that are most required to form the tubular
carriers that transport collagen are downregulated in osteosarcoma!
Examination of the OS genomic profile data[16] revealed that all 22 of the COPII
genes were transcriptionally active in these tumors, indicating that epigentic silencing
was not the cause of the decreased expression of SAR1A, SEC23A, SEC24A, or SEC24D.
Since COPII proteins are ubiquitously expressed, it is reasonable to think they might be
co-regulated in most tissues, although the transcriptional networks that control the
expression of these genes have not been fully elucidated. Nontheless, there are data to
link transcriptional regulation of several COPII components to OASIS/CREB3L1.
CREB3L1 is a member of the bZip transmembrane transcription factors that is closely
related to the UPR transducer ATF6, although unlike the ubiquitiously expressed ATF6
protein, CREB3L1 is more restricted in its tissue expression with particularly high levels
in osteoblasts [91, 137]. The N-terminal transcription factor domain is oriented toward
the cytosol, followed by a transmembrane region and a C-terminal lumenal domain. Like
ATF6, in response to ER stress, CREB3L1 trafficks to the Golgi where the S1P and S2P
proteases liberate the transcription factor domain allowing it to up-regulate target genes
[91]. In osteoblasts, CREB3L1 is activated by BMP2 and drives expression of COL1A1,
as well as other extracellular matrix (ECM) components essential to the differentiation
process [93, 138]. Knock-down and over-expression studies have been conducted in
several model systems to further define CREB3L1 targets, identified SAR1A, SEC24D,
SEC23A, and to a lesser extent SEC24A, and loss of CREB3L1 resulted in the trapping of
ECM components in the ER [94]. Thus, the COPII components most required for
transporting collagen and other ECM components are co-regulated with their cargo in
osteoblasts. We examined CREB3L1 transcript levels in the OS genomic profile dataset
to determine if they were reduced in OS and might account for the lower expression of
our subset of COPII proteins, but we found them to be comparable that observed in
normal osteoblast tissue (Figure A-5). Importantly, CREB3L1 activity is dependent on it
being proteolytically liberated from the membrane by ER stress. However, our studies
revealed that OS tumors and cell lines were experiencing similarly levels of ER stress, as
judged by expression of convential UPR targets, and the CREB3L1 target COL1A1 was
expressed at comparable levels in OS tumors and osteoblast tissue. Together these data
might argue against a link between CREB3L1 activity and levels of this subset of COPII
components. Nonetheless, studies showing that decreasing CREB3L1 expression in
some tissues did not alter COL1A1 levels[138] , and evidence that CREB3L1 protein can
be post-translationally regulated [92]suggests this issue should be more closely examined
in OS. More recently, a number of microRNAs have been identifed that regulate
expression of specific COPII proteins, including those identified in our studies
[139].Although none of these have been shown to regulate more than one COPII
transcript, given that miRNAs are often dysregulated in tumor cells, their expression in
OS should be determined.
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Given that osteoblasts have developed means to ensure that adequate amounts of
SAR1A, SEC23A, SEC24A, and SEC24D are available to transport collagen and other
components of the ECM, it is not clear why OS tumors have decreased expression of
these very proteins. The significance of their down-regulation is underscored by the fact
that this represents the first conserved molecular feature other than blatant genomic
instability for this tumor type. We have considered three possibilities of why this would
be beneficial to a tumor cell.
First, the OS tumor cells are selecting this molecular signature to specificially
reduce collagen-I secretion, an important ECM and osteoid component. Osteoid
secretion is essential for osteoblast differentiation and skeletal formation. During the
process of secreting osteoid, a majority of the osteoblast cells essentially cement
themselves into place within the bone matrix achieving a terminally differentiated state.
These cells are then considered to be osteocytes, which form an interactive network
within the matrix to sense damage, stress and communicate signals to adapt to changes or
repair bone[140]. Osteosarcoma cells maintain a stem-like state and secrete a
disorganized osteoid matrix[100]. Normal osteoid is comprised of ~90% type I collagen
protein, and we surmise that reduced collagen secretion would contribute to this
abnormal matrix composition. Additionally, mechanical stimulation of pre-osteoblasts
supplied by presence of a tightly packed osteoid matrix assists in the transition of a
normal immature cell into a mature osteoblast and eventual osteocyte[141]. Therefore,
decreased collagen secretion and the corresponding abnormal matrix may help prevent
normal osteoblast differentiation. Furthermore, it has been proven that simply changing
the surrounding matrix of an osteocyte can result in the dedifferentiation back into a
osteoblast type cell further signifying the importance of the extracellular osteoid matrix
[142]. It is noteworthy that the 143B OS tumor cell line, which has extremely low levels
of transcripts for COL1A1 and COL1A2, has a very high take rate in xenograft studies
and the subsequent tumors are highly metastatic [122]. Conversely, the SaOS2 cells,
which still secrete low levels of collagen, have a lower take rate and the tumors that do
arise grow comparibly slower and have lower metastic potential[143]. We found that all
108 pediatric OS patient tumors produced both collagen-I transcripts at levels comparable
to those found in normal osteoid lineage cells. In view of the vast genomic instability
associated with this tumor type, it is difficult to understand why collagen levels are not
simply down-regulated in OS until considering secreted collagen-I protein integration
into the ECM is required for the remodeling that occurs during metastsis[144].
A second possibility is that the transport of other secretory pathway protein(s),
which provides a growth disadvantage to OS tumors, is the real target of the reduced
levels of this subset of COPII proteins. Targeted knockdown studies of COPII proteins,
such as SAR1, have demonstrated that secretion of convential-sized proteins might not be
as dramatically affected by their loss as large cargo proteins[47]. Studies investigating
how large cargo are packaged in COPII vesicles have demonstrated that other collagen
types also depend on mega-COPII vesicles for their transport[38]. While we have not
examined the secretion of these proteins, we surmise they too would be effected by the
diminished presence of the subset of COPII proteins, as would other large cargo. As
previously mentioned, skeletal disformaties associated with various coatopathies appear
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to be caused by the inability to secrete collagen and other ECM proteins. A study of a
zebrafish Sec24D bulldog mutant found Sec24D to be essential for secretion of ECM
proteins during chondrocyte differentiation and skeletal development, which relies on a
crosstalk between osteoblasts and the ECM. Loss of functional Sec24D protein in this
model also resulted in a distended ER with accumulated proteins, similar as to what is
observed in OS tumor cells[55]. Importantly, ECM remodeling is critical in tumor
metastasis[144] making this an appealing target of the down-regulation of these COPII
proteins.
A third possibility is that regulation of COPII genes may share transcriptional
activators with other gene(s) critical to OS tumorgenisis. In keeping with this possibility,
CREB3L1, the regulator of this subset of COPII proteins in osteoblasts, has been argued
to be a metastasis suppressor in a rat mammary tumor model, and chip on chip analyses
identified a number of genes involved in cancer development as targets [145]. Similarly,
epigenetic silencing of CREB3L1 is correlated with a more aggressive phenotype in
human bladder and breast cancer [146, 147]. However, genome-wide studies to identify
CREB3L1 targets in OS tumors have not been conducted. To remedy this, we have
initiated further studies involving transcription factor network mapping and genomic
profiling.
In summary, the particularly high genomic instability associated with OS tumors
has precluded the identification of a unifying molecular signature, although a grossly
dilated ER has long been a poorly understood hallmark of this tumor. Our studies
demonstrated this abnormal phenotype was caused by a combination of collagen
production, which places unusual demands on the secretory machinery, and the reduced
expression of four COPII genes essential for the secretion of large cargo, like collagen-I.
This reduction in COPII transcripts was conserved in the majority of 108 OS tumor
patient samples, PDXs and cell lines. Restoring SAR1A and SEC24D protein levels was
sufficent to increase collagen-I secretion and resolve the abnormal ER dilation. This
represents the first conserved molecular signature for OS and understanding how this
must benefit these tumors should provide improved insights into OS tumorigenesis and
potential weakness to exploit.
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CHAPTER 3.

SECRETOME

Introduction

Osteogenesis
Osteosarcoma tumors often arise at the metaphysis of long bones during periods
of rapid growth in adolescents[3]. Bone homeostasis requires a tightly regulated balance
between osteoblasts, osteocytes and osteoclast cells that participate in constant cycles of
remodeling. Osteoclast cells secrete proteases and hydrochloric acid to dissolve existing
bone matrix, which simultaneously recruits immature osteoblasts[148]. Osteoblast cells
are highly dependent on their secretory capacity, as their central cellular purpose is to
form the bone matrix. The immature osteoblast cells are derived from mesenchymal
progenitors and are responsible for the production and secretion of extracellular proteins
collectively rereferred to as osteoid. The nascent matrix consists of abundant amounts of
type-I collagen protein and a lesser abundance of non-collagenous proteins that function
to organize the collagen fibrils. Mineralization of the osteoid is initiated by mature
osteoblasts that use the collagen fibrils as a platform for hydroxyapatite deposition that
results into a hardening of a dense bone matrix that will provide structural support to the
tissue [149]. Upon completion of secretion and mineralization of the osteoid, many of the
osteoblasts become encased within the bone matrix deposited from neighboring cells,
achieving a fully differentiated state as an osteocyte cell. Osteocyte cells constitute about
90% of the existing skeletal cells and form an intricate, interactive network of stationary
cells with long dendritic extensions. These processes reach through narrow canaliculi to
interact with nearby vasculature, neighboring osteocytes, osteoclasts and osteoblast cells,
to orchestrate bone remodeling through expression of osteoprotegerin and receptor umor
necrosis factor ligand superfamily member 11 (RANKL) [140, 150].

Extracellular vesicle secretion
Many tissues contain specialized secretory cells, but even non-secretory cell types
are capable of secreting extracellular vesicles, a trait conserved throughout evolution and
first observed in bacteria[151]. Extracellular vesicles facilitate an exchange with nearby
cells, delivering a vast variety of material including, signaling molecules, proteins, lipids,
and nucleic acids or can function to modulate cell surroundings[152].The term
extracellular vesicle is very broad, and we use it here to encompasses all types of bilayer
membrane bound secreted vesicles. Extracellular vesicles secreted by osteoblasts have
been found to range from 50 – 400nm in diameter, suggesting heterogenous vesicle
origins, that contribute not only to extracellular matrix mineralization, but also to
intercellular communication[153]. The best characterized osteoblast derived
nanoparticles are collagen-anchored matrix vesicles. Typically found to be 100 – 300nm
in diameter, these serve as the first point of nucleation for hydroxyapatite deposition.
Studies suggest that the calcium-phosphate mineralization first occurs within the vesicles
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themselves after firm attachment to the extracellular matrix and eventually erupt due to
crystalline formation, depositing the vesicle components [153, 154]. Recent studies
suggest the contents of the matrix vesicles contain much more than only the start of
hydroxyapatite formation and collagenous structures. The vesicle compositions have been
described to reflect the composition of the parental osteoblast cell, including typically
cytosolically localized enzymes, lipids and even ribosome components and to have great
overlap to other non-matrix derived vesicles that are freely secreted [153]. Osteoblasts
secrete both mineralizing and non-mineralizing vesicles and often referred to as
exosomes, dependent on vesicle size.
Recent studies using murine-derived osteoblasts have established that vesicle
content varies depending on cellular state of differentiation, suggesting they may mediate
distinct functions[155]. The vesicles contain microRNAs (miRNA) and one study
detected high expression of 43 diverse miRNAs in exosomes derived from mineralizing
osteoblasts, demonstrated the direct up-take of the vesicle content into bone-marrow
derived stromal cells and reported the content to significantly promote osteogenic
differentiation. The signaling mediated elevated RUNX2 and alkaline phosphatase (ALP)
expression, as well as altered the recipient cells miRNA expression. The altered miRNA
expression signature directly regulated wingless/integrated (Wnt) signaling, insulin
signaling, and transforming growth factor beta-1 (TGF-) signaling pathways, all of
which positively influence differentiation status into osteoblasts[156]. Furthermore,
secreted extracellular vesicles regulate bone remodeling to maintain skeletal homeostasis.
Specific inhibition of osteoblast vesicle secretion resulted in repressed osteoclast
differentiation and aberrant bone density. Highlighting the pivotal roles these vesicles
facilitate in cell-cell communication to maintain normal physiology. As well as, a
number of miRNAs have been identified in bone-derived vesicles that were specific to
either inhibit or promote osteoblast differentiation[157]. Taken together, these data
suggest that extracellular vesicle cargo, especially miRNAs, are essential to influencing
differentiation statuses of MSCs and maintaining functional bone remodeling.
During OS tumorigenesis the balance between bone formation and reabsorption is
disrupted and tumor vesicle secretion is often dysregulated. Therefore, it is not surprising
that vesicle content can play advantageous roles in tumorigenesis to support
angiogenesis, proliferation and transition to metastasis. Vesicle have been detected in
distant sites at pre-metastatic niches [158, 159]. Similar to non-transformed cells, vesicle
cargo most often reflects the originating cell. However, in a tumorigenic environment
instead of maintaining normal tissue physiology the cross-talk allows manipulation of
surrounding stromal cells (i.e., fibroblasts, macrophages, etc.) to modify the tumor
microenvironment into more favorable conditions, like recruitment of vasculature. The
best example in OS is the evidence of exosomes derived from highly metastatic OS
variants that could be absorbed by poorly metastatic OS and rapidly induce an invasive
phenotype in the recipient cells. In addition, the vesicles derived from the highly
metastatic OS clones were detected to concentrate as pre-metastatic niches of the lungs of
mice and are suspected to act as an attractant gradient to recruit OS cells to distant
sites[160]. Another group found that OS derived exosomes directly stimulated human
umbilical vein endothelial cells (HUVEC) cells to increase levels of pro-angiogenic
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factors, promote invasiveness and formed large vessel-like formations during an in vitro
assay. Exosomes derived from normal osteoblasts did not have this influence. It was
concluded that miRNAs packaged into these extracellular vesicles were the mediators of
these elevated tumorigenic properties[161]. It is evident that extracellular vesicles
secretion plays fundamental roles in both normal and diseased bone.
Our group previously demonstrated the grossly dilated ER morphology observed
in OS tumors is due to a combination of abundant, yet normal collagen production and a
decrease of COPII vesicle proteins, SAR1A and SEC24D, required to export the large,
rigid proteins from the ER. To identify the effect of COPII insufficiency on other cellular
proteins, we chose to investigate parental and COPII restored versions of the 143B OS
cell line. In spite of having reduced levels of SAR1A and SEC24D, 143B does not
express collagen, which we reasoned might mask changes in less abundant proteins. Both
the secreted and cell surface proteomes were determined.

Materials and Methods

Cell culture
The hFOB1.19 cells were obtained from the American Type Culture Collection
(ATCC) and cultured at 34°C with 5% CO2 and grown in DMEM/F-12, no phenol red
(GibcoTM), supplemented with 10% fetal bovine serum and 1% L-glutamine.
Osteosarcoma cell lines 143B were gifts from Dr. Michael A. Dyer (St. Jude Children’s
Research Hospital), cultured at 37°C and 5% CO2 and grown in Dulbecco’s modified
Eagle medium (Corning™), supplemented with 10% fetal bovine serum, 1% Lglutamine, and 0.015mg/ml 5-bromo-2'-deoxyuridine (Sigma-Aldrich), per guidelines of
ATCC.

Real-time PCR
Total RNA was isolated using the RNeasy Kit (Qiagen) from cell pellets. RNA
was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems) and subjected to SYBR® Green chemistry-based qPCR according
to the manufacturer's protocol using the QuantStudio 3 Real-time PCR System (Applied
Biosystems). Primer pairs were obtained from (ThermoFisher Scientific) and sequences
are listed in (Table A- 3). Relative mRNA fold change was computed from the
QuantStudio-generated Ct values by using the 2−ΔΔCt method. hFOB1.19 mRNA levels
were normalized to 1, and OS cells mRNA levels were plotted as a relative measure of
hFOB1.19 levels. Statistical analyses were performed using Prism Ver. 9 (GraphPad
Software) by Student's t-test (unpaired; two-tailed).
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Immunoblotting
Cells were washed twice with PBS and lysed on ice in NP40 lysis buffer (50 mM
Tris pH 7.5, 150 mM NaCl, 0.5% NP-40, 0.5% deoxycholic acid), 0.1mM PMSF and a
protease inhibitor cocktail. Lysates were clarified by a centrifugation of 21,000g for 15m
at 4°C. In all cases, prepared samples were resolved under reducing conditions on SDSPAGE gels ranging from 10% to 12% and transferred to PVDF membranes. Antibodies
used for immunoblotting were anti-SAR1A (Santa Cruz #sc-130463), anti-SEC24D (Cell
Signaling #14687s), anti-GAPDH (Milipore #MAB374) and anti-HSC70 (Santa Cruz
#sc-7298).

Surface protein biotinylation and isolation
Cells were plated in complete DMEM and incubated for 24hrs prior to cell
surface label. Pierce™ Cell Surface Protein Isolation Kit (#89881)was used according to
protocol with minor adjustments. Briefly, cells were washed, biotinylated for 10m, label
removed, and reaction quenched with Tris(+1mM oxidized gluthione). Samples scraped
and lysed on ice 30m, sonicated and lysates clarified by centrifugation at 10,000g for 2m
4C. Labeled proteins were isolated by 2hr incubation with NeutrAvidin. Agarose was
washed in a column and protein eluted by the incubation of SDS-PAGE sample
buffer(+50mM DTT), 1hr RT, followed by centrifugation to collect eluted sample.

Trichloroacetic acid (TCA) precipitation of secreted proteins
Cells were incubated 24hrs in serum free medium. Conditioned media harvested
and passed through a 0.22M filter (Millex-GP SLGP033RS), centrifuged for 5m at 500g
and transferred to new tubes for TCA precipitation. Trichloroacetic acid (100%) cold was
added to samples at a final mixture of 10% TCA. Samples were then briefly vortexed and
incubated 1.5hrs on ice. Centrifuged at 15,000g for 10mins at 4C. Supernatant aspirated
without disturbing pellet. Acetone wash performed with the addition of 0.5ml cold
acetone, vortex briefly, centrifuge 15,000g for 10min at 4C. Aspirate acetone, avoiding
pellet. Repeat wash 2x. Finally, allow acetone to evaporate ~15m, RT and samples
resuspended in 2x Lammeli (+ME) buffer.

Proteome profiling by spectral count MS/MS
The proteins in the gel bands are reduced with dithiothreitol to break disulfide
bond and the Cys residues are alkylated by iodoacetamide to allow the recovery of Cyscontaining peptides. The gel bands are then washed, dried down in a speed vacuum, and
rehydrated with a buffer containing a protease to allow the protease enter the gel. For
routine protein identification, trypsin is used for overnight proteolysis. The next day
digested samples are acidified and the peptides are extracted multiple times. The extracts
are pooled, dried down and reconstituted in a small volume.
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The peptide sample are loaded on a nanoscale capillary reverse phase C18 column
by a HPLC system (Thermo EasynLC 1000), and eluted by a gradient (~75 min). The
eluted peptides are ionized by electrospray ionization, and detected by an inline mass
spectrometer (Thermo Elite). The MS spectra are collected first and the 20 most abundant
ions are sequentially isolated for MS/MS analysis. This process is cycled over the entire
liquid chromatography gradient.
Database searches are performed using Sequest search engine in our in-house
SPIDERS software package. All matched MS/MS spectra were filtered by mass accuracy
and matching scores to reduce protein false discovery rate to ~1%. Finally, all proteins
identified in one gel lane are combined together. The total number of spectra, namely
spectral counts (SC), matching to individual proteins may reflect their relative abundance
in one sample after the protein size is normalized. Moreover, the SC is useful for
comparing the level of the same protein across a number of samples (e.g. control and
immunoprecipitated samples).

QuickGO analysis
GO Term identifiers are indicated in each result panel. Taxon: 9606 Homo
sapiens, Gene products: Protein – UniProtKB identifiers were used from proteomic data.
References: PMID, Evidence: , Qualifier: located_in

Results
143B.ST cells have significantly reduced levels of SAR1A and SEC24D
transcripts and protein compared that of pre-osteoblast control cells, hFOB1.19, and in
fact the levels of these proteins are even lower than that observed in the SaOS2
osteosarcoma line. We previously produced a bulk culture of 143B cells expressing the
dCas9-SunTag-VP64 CRISPR-activation system [119], 143B.ST, which were further
modified by lentiviral integration of a dual sgRNA expressing construct. sgRNAs
targeted to the promoter regions of SAR1A and SEC24D genes were selected based on
their ability to restore expression to levels as similar as possible to those exhibited in
hFOB1.19 cells [Chapter 2]. The SAR1A and SEC24D sgRNA expressing cells are
referred to as 143B.ST(+COPII) and a bulk culture was obtained, and transcripts were
found to be restored near that of osteoblast control cells, but slightly higher for SAR1A at
a fold change of 1.3 in comparison to 1 of hFOB1.19 cells. (Figure 3-1A, B).
Additionally, when steady-state levels of the two COPII targets were detected, it was
evident that protein levels were increased a bit higher than hFOB1.19 (Figure 3-1A, B).
To investigate changes of proteins destined for cell surface localization upon
COPII restoration, we performed a cell surface biotinylation and protein isolation assay
on 143B.ST and 143B(+COPII) cells (Figure 3-2A). Fold change analysis with a pvalue cut-off of <0.001 resulted in only 17 differently expressed proteins. Nine of the 17
proteins were actually decreased in 143B.ST(+COPII) in comparison to the non-COPII
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Figure 3-1.

143B(+COPII) cells exhibit restored SAR1A and SEC24D expression.

(A,B) qRT-PCR data of 143B.ST and 143B(+COPII) SAR1A and SEC24D transcripts
were normalized relative to hFOB1.19 cells, n=3. SDS-PAGE analysis of hFOB1.19,
143B.ST and 143B(+COPII) lysates were probed for SAR1A and SEC24D protein.
GAPDH or HSC70 was provided as a loading control. Statistical differences of the assays
were computed using unpaired, two-tailed Student’s t-tests, and are indicated as *P≤0.05,
***P≤0.001 and ****P≤0.0001. Error bars indicate mean ± SD.
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Figure 3-2.

143B(+COPII) surface proteomics changes.

(A) Graphic summary of cell surface protein isolation experiment. Cells were grown
24hrs, briefly biotinylated, quenched, thoroughly washed, lysed and pulled-down with
NeutrAvidin to isolate surface labeled proteins for mass spectrometry.(B) Significant
differentially expressed surface assay proteins subcellular localizations were identified
with QuickGo database. True cell surface protein’s expression were transformed to log2
and fold change calculated.
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restored 143B cells (Table 3-1). To determine if we were detecting true surface proteins,
QuickGO [162] was used to determine subcellular localization of the significant
proteomic hits at a cut-off of <0.05 resulting in 99 differentially expressed proteins.
While there is some of overlap of proteins identified in the GO cellular components, data
revealed that only eight out of the 99 differentially expressed proteins have been
demonstrated to have a cell surface localization (Figure 3-2B). Furthermore, only one of
the annotated surface proteins, Complement C1q Binding Protein (C1QBP), was detected
to have been elevated in 143B.ST(+COPII) samples. Thus, there was no significant effect
of COPII insufficiency on the trafficking of cell surface proteins.
Non-membrane bound secreted proteins are initially transported to the Golgi
apparatus in COPII vesicle for modifications, so we examined the effect of COPII
restoration on the general secretome. First, 143B.ST and 143B.ST(+COPII) were tested
for their ability to grow for 24hrs in serum free medium without losing viability or
inducting the unfolded protein stress response in order to prevent protein contamination
from fetal calf serum.
We found that cells remained viable and exhibited minimal UPR activation during
24 hrs of serum withdrawal (Figure B-1). Secreted proteins present in 24hr serum-free
cultured media were harvested, TCA precipitated, and samples submitted for spectral
count mass spectrometry. Proteomic analysis of the non-membrane bound secretome
revealed a dramatic increase in differential expression of secreted proteins from the
143B.ST(+COPII) restored cells relative to 143B.ST that could initially be observed by
GelCode Blue staining of the SDS-PAGE gel before sample submission (Figure 3-3A).
Each sample was submitted in duplicate and the secretome profiling by spectral count
data was transformed to log2 and the fold change calculated. These fold change values
were plotted against the -log10 of the P-value with all significant hits of P <0.001
indicated in red. We detected a total of 234 secreted proteins to have significant
differential expression with p-value of <0.05, and 162 of these proteins met a cut-off pvalue of <0.001 (red) (Figure 3-3B). The top proteomic hits with a cut-off of P <0.001
were analyzed in the Gene Ontology database, QuickGO, for mapping of subcellular
localization (Figure 3-3C). Surprisingly, the results indicate the majority of the proteins
were considered to be intracellularly located. Only 18% or 29 of the original 162 (p-value
<0.001) are secreted proteins that have been demonstrated to traffic through the secretory
pathway. Further analysis of the <0.001 significant differentially expressed proteins
demonstrated that 79% of them have previously been identified in extracellular exosome
studies, indicating a possible link between COPII and extracellular vesicle secretion,
which has not been reported (Figure 3-3C).
To further analyze this data, we compared proteins identified in the cell surface
isolation to those detected in the secreted material (Figure 3-4A). There were 155
overlapping proteins detected in both datasets. The majority were detected to be
decreased in cell surface samples and upregulated in conditioned media. However, when
we limited this to those showing a significant differential expression of p-value <0.05, the
number reduces to only ten shared proteins. Comparatively, when we separated out data
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Table 3-1.

143B(+COPII) top differentially expressed surface assay proteins.

Uniprot | Gene
P14136|GFAP

Log2 fold change
2.50
****

Subcellular localization
cytoplasm

Q16643|DREB

1.28

****

cytoplasm

P62753|RS6

0.86

****

cytoplasm

Q15149|PLEC

0.83

****

cytoplasm

O00159|MYO1C

0.65

****

cytoplasm

P08670|VIME

0.61

****

cytoplasm

P35579|MYH9

0.52

****

cytoplasm / cell membrane

P35580|MYH10

0.42

****

cytoplasm / secreted

Q86UP2|KTN1

-0.87

****

endoplasmic reticulum

P42704|LPPRC

-0.97

****

nucleus

Q9UQE7|SMC3

-1.32

****

nucleus

P49792|RBP2

-1.44

****

nucleus

Q14683|SMC1A

-1.59

****

nucleus

P55287|CAD11

-1.63

***

cell membrane

O60568|PLOD3

-1.75

****

endoplasmic reticulum / secreted

O60313|OPA1

-1.86

****

mitochondrion

Q9H6B4|CLMP

-2.32

****

cell membrane

*P≤0.05, ***P≤0.001 and ****P≤0.0001.
The p value is derived by G-test [163].
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Figure 3-3.

Freely secreted proteins are significantly elevated in 143B(+COPII).

(A) 143B.ST and 143B(+COPII) cells were grown 24hrs serum free, conditioned media
harvested and TCA precipitated and run on 4-20% SDS-PAGE gel and stained with
GelCode Blue. (B) Spectral counts were transformed to log2, averaged for biological
replicates and fold change calculated. Fold change values were plotted against the -log10
of the P-value with all significant hits of P <0.001 indicated (red). Protein of interest,
TSP1 (light blue). The p-values were derived by G-test [163]. (C) Uniprot IDs of
significant differentially expressed proteins were run in QuickGO for subcellular
mapping and extracellular exosome studies.
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Figure 3-4.

143B(+COPII) overlapping surface and secreted protein hits.
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that express a significant increase in expression in both samples, this results in a final six
proteins; filamin-A (FLNA), alpha-actinin-1 (ACTN1), Ribosomal Protein S3 (RS3), D3-phosphoglycerate dehydrogenase (SERA), plectin (PLEC), and gelsolin (GELS)
(green) (Table 3-2). Finally, while all six of these proteins are not traditional secretory
cargo, all have been identified in previous extracellular exosomal studies and therefore
mapped to GO:0070062.
Studies have demonstrated that secreted vesicles can have dramatic regulating
effects on surrounding cells and are capable of influencing differentiation states.
Secretory miRNAs have been established to have some of the most influential effect on
differentiation and while that is outside the scope of this project, Davies, et al.[153]
demonstrated that extracellular vesicle content is temporally regulated during phases of
osteoblast differentiation. Therefore, we were curious to explore how proteome changes
in the 143B(+COPII) vs the non-COPII restored parental line would compare with the
changes observed in Davies, et al. manuscript. Our study did not perform the same assay
as the Davies group, in which they specifically isolated secreted vesicles and our mass
spectrometry analysis is different, so we cannot directly compare numerical peptide
values. However, we did compare the proteins identified. The (Figure 3-5) heatmap
displays overlapping proteins determined to be upregulated during the final week of
differentiating osteoblast in the Davies study, the most mature differentiation phase. We
found that while Davies group identified 64 upregulated proteins in the extracellular
vesicles in comparison to earlier phases of osteoblast differentiation, that 26 of these were
present in our non-membrane bound proteome analysis. Of the 26 proteins, all except two
were detected to be increased in the conditioned media of the 143B(+COPII)
osteosarcoma cells compared to 143B.ST.

Discussion
Osteoid deposition is a requirement for the diagnosis and classification of an
osteosarcoma tumor cell indicating the cells are committed at least partially to the
osteoblast lineage. Secretory pathway proteins, such as collagen the main component of
osteoid, destined to reside at either the cell surface or to be secreted, are synthesize in the
ER. After passing quality control measures that ensure their proper maturation, they are
transported out of the ER in COPII vesicle and traffic through the organelles of the
secretory pathway to reach their final destination. In this study we sought to determine if
the COPII insufficiency we identified in OS tumor cells might selectively inhibit the
transport of a subset of cell surface or secreted proteins that would be detrimental to some
aspect of tumor sustainability or metastasis.
Due to the fact that in each case there is at least one homologue for the COPII
proteins that are deficient in osteosarcomas and that most proteins are readily packaged in
the smaller 80 nm vesicles, it is probably not surprising that classical cell surface and
secretory pathway proteins remained mostly unaffected. However, we did find that >200
non-membrane bound proteins were significantly increased in the 24 hr conditioned
media of the 143B(+COPII) restored cells. This result was surprising because the only
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Table 3-2.

143B(+COPII) shared significant differentially expressed proteins.

Uniprot | Gene
P21333|FLNA

Cell surface proteome
fold change
0.37
*

Non-membrane bound
proteome fold change
1.79
****

P12814|ACTN1

0.42

*

0.63

****

P23396|RS3

0.66

*

2.06

****

O43175|SERA

0.34

*

1.11

****

Q15149|PLEC

0.83

****

1.26

*

P06396|GELS

1.70

***

1.21

*

P14314|GLU2B

-1.22

*

2.09

****

O43390|HNRPR

-0.76

*

1.72

***

P38646|GRP75

-0.49

*

0.76

*

Q12906|ILF3

-1.16

*

0.76

*

P02545|LMNA

-0.80

*

0.63

ns

P05783|K1C18

0.49

*

0.46

ns

P35268|RL22

0.76

*

0.46

ns

Q02809|PLOD1

-1.13

*

0.46

ns

P12111|CO6A3

-0.76

*

0.20

ns

P08670|VIME

0.61

****

0.31

ns

P07355|ANXA2

-1.55

*

0.56

ns

Q07021|C1QBP

1.39

*

0.29

ns

P10809|CH60

-0.66

*

0.17

ns

*P≤0.05, ***P≤0.001 and ****P≤0.0001.
The p values were derived by G-test [163].
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Figure 3-5.

Overlapping vesicle content of mature differentiated osteoblasts.

Non-membrane bound secretome hits were analyzed for overlap with proteins identified
in Davies, et al.[153] mature-osteoblast derived exosome cargo. Spectral counts were
transformed to log2.
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difference between the 143B.ST and 143B.ST(+COPII) tumor cells was the restored
expression of SAR1A and SEC24D protein expression to that of a normal osteoblast
cells, hFOB1.19. Tumor derived exosomes and other extracellular vesicle have been
found to be critical regulators of tumorigenesis and modulators of the tumor
microenvironment [164, 165]. As of today’s literature there is not strong evidence to
indicate that SAR1A or SEC24D are involved in functions other than that of COPII
vesicle formation for ER to Golgi apparatus vesicle trafficking[166]. Though previously,
Sec24p, the Saccharomyces cerevisiae ortholog of mammalian SEC24D was implicated
in endocytosis, which normally occurs through clathrin-coated COPI vesicles, although
the data to support this claim is limited [167]. The majority of our protein hits have been
previously identified as exosome cargo. Exosome biogenesis occurs when late endosomes inwardly bud forming vesicles resulting in multi-vesicle bodies (MVBs). The
MVBs then can either fuse with the plasma membrane to release the exosomes or with
the lysosome to degrade the exosomal cargo[168]. While, classical exocytosis from the
Golgi apparatus involves clathrin-coated granules budding from the organelle and either
directly fusing with the plasma membrane or with the MVBs [169]. Yet, results indicate
that the majority of the proteins identified in our study would not have been synthesized
in the ER, so it is not evident how the restored expression of SAR1A and SEC24D would
directly impact the secretion.
We were surprised to find that the majority of differential protein expression
observed from the cell surface assay were proteins decreased in expression in the
143B(+COPII) cells. We had in fact anticipated the opposite by restoring COPII vesicle
secretion, expecting to see an increase in surface receptors. C1QBP was the only true cell
surface localized protein increased in our 143B(+COPII) cells. C1QBP, is an ambiguous
protein expressed in most cells types and often upregulated in tumors[170, 171]. It is
found located ubiquitously throughout cells, including the plasma membrane. It’s role in
osteosarcoma has not yet be investigated, but it has found to support the hepatic
metastasis of pancreatic cancer through its interactions with IGF/IGFR signaling cascade
and increased expression in breast cancer is considered a poor prognosis marker [172,
173]. Therefore, while we assume that it would not be beneficial for an osteosarcoma cell
to repress secretion of surface C1QBP, further investigation would be required.
Additionally, this assay should be repeated before final conclusions are made. A
substantial number of proteins identified in this assay are non-cell surface localized and
the overlapping proteins identified with the non-membrane bound proteome study mostly
do not correlate. It should be taken into consideration that the Sulfo-NHS-SS-Biotin label
can be cell permeable and even though the label time was reduced, reaction quenched,
and cells washed thoroughly there is the possibility for experimental error here.
The non-membrane bound proteome assay’s methods are more straight forward
and multiple biological replicates (n=4) produced similar results of an abundant increase
in secreted proteins in the 143B(+COPII) conditioned media compared to 143B.ST cells.
We performed these experiments because we had considered the possibility that the
COPII vesicle secretion was advantageously repressed. When we restricted our hits to
proteins that travel the traditional secretory pathway using COPII vesicles,
Thrombospondin-1 (TSP-1) was identified [174]. TSP-1 was an interesting candidate that
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a tumor cell may select to repress because it secreted by a variety of normal and
malignant cell types and has been implicated as having both pro- and inhibitory
tumorigenic properties [175]. Upon extracellular secretion TSP-1 is incorporated as part
of the matrix interacting with other matrix proteins, cell surface receptors and growth
factors. It has specifically been demonstrated to regulate collagen-I homeostasis and
absence is associated with disorganization of collagen fibrils, a phenotype that is also
observed in extracellular matrix deposition surrounding osteosarcoma cells[176]. Yet, the
protein was best characterized in endothelial cells for its antiangiogenic properties,
inhibition of cell proliferation and migration, as well as its ability to induce apoptosis
[177, 178]. The N-terminal region of the TSP-1 contains a domain homologous to
procollagen. It has been demonstrated that the majority of the regulation of antiangiogenics is though this TSP-1 domain interactions[175]. Yet despite TSP-1’s antitumorigenic effects in endothelial cells, it has been found to have pleiotropic anti- and
pro-tumorigenic effects in various tumor types[175]. TSP-1 was also demonstrated to be
a regulator of bone remodeling with the ability to promote proliferation of pre-osteoblast
cells, while inhibiting differentiation, a function that could be considered beneficial to
osteosarcoma tumor cells [179]. Furthermore, TSP-1 knockdown in osteosarcoma cells
examined both in vitro and in vivo showed dramatic repression of tumor cell migration,
invasion and metastatic spread and therefore would not be beneficial for an osteosarcoma
cell to selectively prevent secretion [180]. When we consider all the secretory protein
changes observed in both the surface protein and non-membrane bound secretome assays
it becomes evident that the majority of the proteins identified for significant differential
secretion would actually be beneficial for a tumor cell to increase secretion of (eg. TSP-1,
MMPs, etc). Therefore, the question remains of why is COPII vesicle secretion decreased
in pediatric osteosarcoma cells?
Both osteoblast and malignant osteosarcoma extracellular vesicle contents are
heterogenous and often contain proteins considered to be localized to the cytosol or
nucleus and reflect the parental cell [181-183]. There have been a number of studies
performed to examine the proteomic contents of these vesicles and similar to other
studies, we observed a large overlap of secreted proteins identified in other extracellular
vesicle studies[183]. However, studies by Davies et al. [153] have identified the content
of the extracellular vesicles secreted by osteoblasts to be temporally regulated during
differentiation. This group harvested secreted vesicles from primary osteoblasts at early,
intermediate, and final differentiation phases over a 3-week period. Their study
concluded that while there is a lot of overlap of vesicle content, the majority of proteomic
changes occurred at week 3 during the mature phase of differentiation. When we
compared our non-membrane bound proteome data, we found that a number of the
significantly increased proteins from 143B(+COPII) cells overlapped with those
temporally upregulated in vesicles during the most mature phase of osteoblast differentiation in their study. In addition to this, Davies et al. and others have demonstrated that
the addition of osteoblast derived extracellular vesicles to mesenchymal stem cell
cultures leads to enhanced differentiation[184, 185]. The fact that the COPII restored
cells appear to reflect a more mature differentiated secreted proteome leads us to
hypothesize that possibly there could be benefits for a tumor cell secretome to reflect that
of an immature cell. However, while there remains much to be done to substantiate the
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significance of these findings, we would be curious to explore if the proteome of these
cells is supporting an immature bone matrix conducive to tumorigenesis.
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CHAPTER 4.

FINAL DISCUSSION

To date the best characterized aspect of pediatric osteosarcoma is the wide-spread
genomic instability that drives the tumor formations. Genome-wide studies have been
successful in identifying possible driver gene mutations and dysregulated pathways, but
the genetic instability has made it difficult to concretely define mutations that occur
consistently and that are druggable, owing to heterogeneity[13, 110]. Early studies of OS
involved detailed ultrastructural analyses that led to the identification of the dilated ER
phenotype as the ‘hallmark’ morphological feature of these tumor cells[14, 15]. We
decided to investigate this unusual morphology as it appeared to be the common
denominator between most patients.
Initially, when we observed the dilated ER, we suspected the canonical UPR to be
activated in these tumors because these signaling cascades are often selectively controlled
in tumors to provide survival advantages and are linked to ER-membrane synthesis
allowing an extended ER morphology. However, using three commonly used OS cell
lines and an osteoblast line, we discovered that UPR wasn’t robustly activated in the OS
beyond that observed in the osteoblast, although the OS cell lines were capable of
responding to pharmacological UPR inducers. Through a combination of metabolic
labeling, western blotting, and RNA-Seq studies we determined that a subset of COPII
proteins required to transport proteins from the ER to the Golgi were transcriptionally
downregulated in OS. Specifically, SAR1A, SEC23A, SEC24A, and SEC24D were
identified to have decreased expression in three OS cell lines, two xenografts and the
majority of 108 pediatric patient tumor samples comparatively to normal osteoblast
tissue. Inspection of the large WGS data sets from OS samples revealed altered levels of
SEC24D transcripts have been previously observed and included in publications[13].
However, we believe this molecular signature has remained over-looked until now,
because these proteins are not expected to function as tumor drivers.
Although non-secretory tissues may not be morphologically affected by lower
COPII gene expression, osteoblasts and osteosarcomas secrete an abundance of collagenI, a large and rigid protein that puts a substantial demand on the secretory ER to produce
mega-tubules that can require at least double the COPII proteins to form. We were able to
demonstrate that restoring COPII proteins in OS cell lines resulted in increased collagen-I
secretion, with less procollagen-I remaining in the cells, and restored a normal ER
morphology. Consistent with these findings, restoration of both procollagen-I transcripts
in osteolytic 143B OS cells resulted in a dilated ER morphology. We firmly believe we
have demonstrated that the combination of decreased COPII proteins and high secretory
demand is the cause of the grossly extended ER morphology associated with OS.
Additionally, we believe that decreased SAR1A, SEC23A, SEC24A and SEC24D
expression provides a novel and highly conserved molecular signature for the notoriously
variable pediatric osteosarcomas. The important question that must be asked is why
would this molecular signature be so beneficial to OS that is conserved across the vast
majority of patient tumors? We hypothesized there were three likely possibilities
addressed in (Tables 4-1 and 4-2).
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Table 4-1.

Comparison of (-/+) COPII restored SaOS2 and 143B OS cell lines used in vivo.

Cell line comparison
:
COPII:
Collagen-I secretion:

Table 4-2.

Tumor
growth:

Disrupted

143B.ST
143B(+COPII)
Do not produce collagen-I
COPII insufficient
COPII restored

Secretes

n/a

n/a

Three hypotheses & anticipated in vivo orthotopic study outcomes.

Hypotheses

Cell lines:

SaOS2.ST
SaOS2(+COPII)
Produce collagen-I
COPII insufficient
COPII restored

(I)
Collagen-I secretion is
detrimental to tumor growth.

SaOS2.ST vs
143B.ST vs
SaOS2(+COPII) 143B(+COPII)
Sa.(+COPII)
Decreased

No
difference

(II)
Unidentified protein(s)
secretion is detrimental to
tumor growth.
Expected in vivo outcome?
SaOS2.ST vs
143B.ST vs
SaOS2(+COPII) 143B(+COPII)
Sa.(+COPII)
Decreased
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14.(+COPII)
Decreased

(III)
COPII proteins are co-regulated
with another protein critical to
tumorigenesis.
SaOS2.ST vs
SaOS2(+COPII)

143B.ST vs
143B(+COPII)

No
difference

No
difference

The first hypothesis we contemplated is that the tumor cells have selected to
reduce expression of COPII transcripts for the advantage of limiting collagen-I deposition
specifically. The second, the beneficial target of decreased COPII expression and reduced
transport through the secretory pathway is not collagen but another currently unidentified
cell surface or secreted protein(s) that would be detrimental to tumor growth. The third
hypothesis we have considered is that COPII gene transcripts could be co-regulated with
other protein(s) critical to repress for OS tumorigenesis and the decreased COPII
transcripts are a side-effect of a more critical target. Most simply, restoring the four
COPII gene expression, SAR1A, SEC24D, SEC23A, and SEC24A in both SaOS2 and
143B OS lines and comparing them to the control lines in orthotopic in vivo studies
would be most direct to address our three hypotheses.
We have begun in vivo orthotopic studies using the four (-/+) COPII restored cells
to compare survival outcomes and tumor growth between the two OS groups,
summarized in (Table 4-1). SaOS2 cells produce collagen-I protein and therefore
externally secrete it in SaOS2(+COPII), while 143B does not transcribe collagen-I genes.
If collagen-I is selectively repressed because it negatively effects tumor growth we
should observe variations in tumor growth of SaOS2(+COPII) relative to parental
SaOS2.ST, but not in the 143B(-/+)COPII restored tumors because they do not make
collagen. However, current literature suggests that preventing collagen secretion would
not be beneficial to a tumor. Extracellular matrix remodeling is a critical step to
tumorigenesis and metastatic spread. It has been thoroughly demonstrated that the most
common modification to extracellular matrices in the tumor environment is the increased
deposition of fibrillar collagen, especially type-I fibrillar collagen. This results in tissue
stiffening to displace normal tissue and a whole range of other tumorigenic support[144].
While it does not appear logical that selectively decreasing collagen-I secretion would be
beneficial to OS tumorigenesis nor to influence tumorigenic properties of the cells, it
could still be covered by the in vivo study. Therefore, initially we investigated both
proliferation and invasion of a collagen-I membrane upon COPII restoration in SaOS2
and 143B cells. Results revealed that restoring COPII protein levels did not affect either
proliferation or invasion characteristics of the cells, preliminarily suggesting hypothesis
one to be untrue (Figures B-2 and B-3). In addition, if decreased collagen-I secretion was
beneficial, we might have expected that the genomic instability that characterized OS
would have resulted in down regulation of collagen-I transcripts in patient tumors.
Instead, we found that majority 108 pediatric OS tumors analyzed continued to produce
high levels of both COL1A1 and COL1A2 transcripts.
Next, we considered the possibility that these tumors have evolved to alter COPII
transcripts to limit trafficking of a currently unidentified secreted and/or membrane
protein(s) that could be detrimental to cell progression. The in vivo study outcomes would
have supported this hypothesis if there was an observed decreased tumor burden in both
SaOS2(+COPII) and 143B(+COPII) compared to their non-COPII restored parental lines,
summarized in (Table 4-2). There are a variety of proteins that once secreted could have
the potential to affect successful tumorigenicity, such as secreted tumor suppressor-like
proteins. For example, secreted frizzled-related proteins can act as Wnt signaling
antagonists and are often detected to be epigenetically silenced in different tumor types
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and advantageously downregulated in osteosarcoma[186]. There is also the possibility
the tumor cells are evading immune detection by suppressing receptors from reaching the
cell surface. We have initiated studies to address this in two different ways. First, we
have begun the orthotopic in vivo studies. If this is hypothesis was true, we would
anticipate that both SaOS2 and 143B COPII restored cell lines would show decreased
growth in vivo. However, preliminary results of an orthotopic xenograft [187] study using
the 143B(-/+COPII) restored cells disproves hypothesis 2, as there were no differences in
tumor growth identified in the study monitored by both weekly luciferase imaging and
caliper measurements (Figure B-4A, B), in vivo techniques further covered in (Appendix
C). Although, it should be taken into consideration that immunocompromise mice were
used and only SAR1A and SEC24D levels were restored. In a complimentary approach,
we performed spectral count mass spectrometry analyses on the parental and COPII
restored 143B OS line to identify changes in the secretome, as well as the cell surface
expression of proteins. The non-membrane bound secretome revealed >200 secreted
proteins to be significantly upregulated comparatively to non-COPII restored cells.
Surprisingly, the majority of proteins identified were not typical bona fide
secretory proteins that are co-translationally synthesized into the ER and use COPII
vesicles for trafficking to the Golgi. However, when we analyzed the significant
secretome hits for proteins that would be detrimental to tumor survival. Overall, it
appeared the proteins that were differentially increased would mostly support
tumorigenesis (i.e., growth factors and metalloproteinase), as well as a number of
cytoskeleton proteins. We are not sure why we observed a dramatic increase of
cytoskeleton protein secretion. However, they do facilitate the dynamic transfer of
secretory vesicles to different locations and therefore may be upregulated in
correspondence to the increased COPII vesicle activity, though this remains to be
proven[188]. Additionally, it should be noted that previous studies have demonstrated
that tumor-derived exosomal cargo contain cytoskeletal proteins and that the vesicle
content was rapidly taken in by tumor-associated macrophages. The cytoskeletal-cargo
was detected to efficiently mediate cytoskeleton rearrangement and has been implicated
as transforming the macrophages more tumor favorable[189]. Taken together these data
suggest that it is unlikely the tumors are selectively repressing COPII to prevent protein
secretion.
However, it should be noted there are limitations to both spectral count
spectrometry and to using the 143B(+COPII) cell line. Spectral count is relatively weak
at quantifying low expression peptides and is considered an only semi-quantitative
technique. We know that COPII vesicle secretion is still occurring in our OS cell lines,
but just at an insufficient capacity. Therefore, depending on the abundance of the
hypothetical ‘critical’ protein we could miss detection all together of it if peptide levels
are low to begin with. Again, the same caveat is the secretome studies have only been
performed in 143B-OS cell lines in which we have restored only SAR1A and SEC24D,
whereas SEC23A and SEC24A are also significantly decreased in the majority of patient
tumor samples and remain low in our “COPII-restored” lines. Yet, it was sufficient to
restore only SAR1A and SEC24D to increase collagen-I secretion in the OS cell lines.
However, there is still a lot about COPII biogenesis not known and it would be logical if
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the tumor cells have evolved to decrease four gene paralogs specifically, that they all
might be required for the secretion of a specific protein. Therefore, to best validate any
findings would be to take a more unbiased approach and preform secretome analyses on
patient-derived xenografts (-/+)COPII restoration of all four genes if possible or at least
additionally OS cell lines with SAR1A, SEC24D, SEC23A, and SEC24A restored. Any
identified proteins can be further validated with metabolic labeled secretion assays and
overexpression studies to determine effects on toxicity, proliferation, invasion, etc.
The only difference between the 143B(+COPII) cells and parental 143B was the
expression of SAR1A and SEC24D back to levels of a pre-osteoblast. However, the bulk
of the secreted proteins had been previously identified in exosomal vesicle content
studies, suggesting a possible link between COPII biogenesis and exosomal secretion,
which has never been reported in current literature. This highlights another limitation to
our study. Our general non-membrane bound secretome was performed on conditioned
media, which will include all types of secretion (i.e., exocytosed, exosomal,
nanoparticles, matrix vesicles, etc.). Thus, we are observing a very general and broad
image of everything secreted over a 24 hr window. Exosomes are produced via inward
budding by late endosomes resulting in MVBs and do not interact with the conventional
secretory pathway organelles at that point. Therefore, it is not abundantly clear how
restored levels of SAR1A and SEC24D effected non-conventional secretion. However,
while investigating this is outside the scope of this study, we would need to specifically
isolate exosomes to determine if we are truly affecting them or another type of secretion.
We also now currently have a wealth of data, including RNA seq analyses, cell surface
proteomics, general secretome data, and we have initiated TNT mass spectrometry
analyses to account for the limitations of spectral count. TNT spectrometry allows us to
take a quantitatively deeper and unbiased approach to analyze internal proteome changes
of SaOS2(-/+) COPII, 143B(-/+) COPII and normal pre-osteoblast line, hFOB1.19. This
method is more efficient at identifying low peptide expression and we have included
phospho-proteome analysis to investigate if perhaps certain proteins are not posttranslationally modified correctly. Therefore, we can use this data together to get detailed
picture of both transcriptional, translational, and post-translational changes that have
occurred upon COPII restoration. We could also specifically look at genes and proteins
known to contribute to exosome biogenesis to elucidate changes, but currently we are
applying these data sets to address our third hypothesis.
Finally, as preliminary data disproved hypothesis one and two, we have
contemplated that the conserved molecular signature is actually a side-effect of the
regulation of another protein(s) that is critical to OS tumorigenesis. We hypothesize that
SAR1A, SEC23A, SEC24A and SEC24D possibly share transcriptional activators with
other protein(s) that may provide tumor advantage to selectively downregulate. The
modified expression of the transcriptional regulators would result in a second-hand effect
of reduced expression of COPII genes, suggesting it as characteristic phenotype instead
of critical function for the advantage of the tumors. The fact that 143B-OS cells do not
produce collagen-I nor have a dilated ER yet are highly metastatic is consistent with this
hypothesis. However, as previously mentioned, there is not a lot known about COPII
transcriptional regulation. Most of what has been discovered is fairly recent and appears

64

to be connected to non-conical UPR regulators CREB3L1/OASIS and
CREB3L2/BBF2H7[91, 93, 94, 97, 99, 190].
Both proteins are tissue-specific paralogues of the ATF6 UPR transducer, with an
N-terminal transcription factor domain positioned to the cytosolic side of the ER, a
transmembrane region, and a luminal domain suspected to sense stress. CREB3L1 is the
tissue specific UPR regulator that has high expression in osteoblast cells and CREB3L2
is reported to have high expression in chondrocytes. Structurally, these two paralogs are
similar and CREB3L1 has been demonstrated to transcriptionally activate SAR1A,
SEC23A, SEC24A, and SEC24D and similarly, CREB3L2 has been demonstrated to
activate SEC23A, SEC24D and other COPII transcripts determined critical to megatubule formation for collagen trafficking. They both appear to activate similar to ATF6,
resulting from an increase in protein synthesis triggering ER stress and stabilizing the
proteins, which are then transported in COPII vesicles to the Golgi apparatus. The ER
proteins are then processed by intramembrane proteolysis to liberate the N-terminal
active transcription factor, which among other genes upregulates these subsets of COPII
subunits. The mechanism of shutting down these signaling cascades has not been
completely elucidated, but it is proposed that reduced ER protein load results in increased
turn-over of the CREB proteins once again. Interestingly, CREB3L1 has been reported to
be epigenetically silenced in bladder and breast cancer correlating to highly metastatic
tumors with poor prognosis[146, 147]. Additionally, the restored expression of
CREB3L1 in murine in vivo breast cancer models resulted in reduced tumor burden and
metastatic spread and no ER dilation was reported in these studies [145]. This data
suggests that inhibiting this ER protein’s function is beneficial to tumorigenesis in
multiple tumor types.
However, transcriptional expression data available from the PeCan database of
CREB3L1/OASIS reveals expression to be normal, if not slightly increased in the majority
of OS patient samples (Figure A-5A, B). Taken together this data supports CREB3L1 as
a positive regulator of procollagen-I gene transcription and OS cells produce an abundant
yet normal volume of procollagen. Though it should be noted that CREB3L1 is not the
sole regulator of collagen-I transcripts because in knockout studies transcripts were still
transcribed, just at lower levels. Importantly, given that CREB3L1 must be posttranslationally processed to be active, it is critical that both proteolysis and translocation
to the nucleus is examined to be fully functional.
Additionally, although CREB3L2 is reported to be more specific to chondrocytes,
we also examined its expression [99]. Interestingly, when we preformed fold-change
analyses on CREB3L2 expression in the PeCan database, we found that that the majority
of the 108 OS tumor patient samples had decreased expression of CREB3L2 relative to
normal osteoblast tissue. Examination of RNA-seq data from our OS cell lines revealed
that CREB3L1 levels were increased compared to the hFOB line, but CREB3L2 levels
were significantly decreased. Furthermore, the genomic profiling data performed on OSPDXs, revealed repressive signatures for CREB3L2 suggesting the possibility of
epigenetic silencing. However, there are currently no studies reporting CREB3L2 to be
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epigenetically silenced in any cancerous tissues nor studies providing evidence of antitumorigenic properties.
The origin cell of osteosarcoma has been difficult to definitively identify because
of the genomic complexity of the disease. However, it is currently agreed to fall
somewhere between a mesenchymal stem cell (MSC) and an osteoprogenitor due to the
production of osteoid and expression of osteonectin, osteocalcin and ALP [1, 93].
Perhaps, OASIS is directly regulating procollagen-I gene expression as is typical of an
osteoblast cell, but that maybe CREB3L2 is the primary regulator of COPII transcription
in these tumors. Conversely, a study in medaka fish has demonstrated CREB3L2 to
regulate COPII transcripts, like TANGO1 during embryonic development, however we
did not find TANGO1 to be affected in OS tumors [99]. Interestingly, CREB3L1/OASIS
but not CREB3L2 has previously been reported to be epigenetically silenced in bladder
and breast cancer and has been demonstrated to repress metastasis and angiogenesis of
these tumors [145-147].To explore these ideas, we could transduce these cells to express
CREB3L2 wild-type and mutant cDNA clones. The effects on COPII gene and protein
induction would be quantified, as well as the effect on tumor growth and metastases in
xenograft studies. In addition, we are currently collaborating with the computational
biology department at SJCRH to explore transcription factor mapping of COPII genes
both in pre-osteoblast and osteosarcoma cells. It would be interesting to use ChIP
sequencing methods to specifically investigate if COPII genes are regulated by both
CREB3L1 and CREB3L2 in OS tumors and to identify other genes that are co-regulated.
In conclusion, we have determined the cause of pediatric osteosarcoma ER
dilation to be caused by a combination of decreased COPII proteins and abundant
procollagen-I production. The reduced availability of COPII proteins is preventing
procollagen-I packaging into COPII mega-tubules and resulting in accumulation within
an overcrowded, dilated ER. However, why these COPII transcripts are reduced remains
to be determined. Additionally, future studies investigating transcriptional regulators of
COPII may reveal previously overlooked disrupted and hopefully druggable targets in
OS.

66

LIST OF REFERENCES

1.
2.
3.
4.
5.
6.
7.
8.
9.

10.

11.
12.
13.

14.

15.
16.
17.
18.

19.

Mutsaers, A.J. and C.R. Walkley, Cells of origin in osteosarcoma: mesenchymal
stem cells or osteoblast committed cells? Bone, 2014. 62: p. 56-63.
Misaghi, A., et al., Osteosarcoma: a comprehensive review. SICOT-J, 2018. 4: p.
12-12.
Taran, S.J., R. Taran, and N.B. Malipatil, Pediatric Osteosarcoma: An Updated
Review. Indian J Med Paediatr Oncol, 2017. 38(1): p. 33-43.
Liu, J.J., et al., Telangiectatic osteosarcoma: a review of literature. Onco Targets
Ther, 2013. 6: p. 593-602.
Nakajima, H., et al., Small cell osteosarcoma of bone. Cancer, 1997. 79(11): p.
2095-2106.
Inwards, C.Y., Low-Grade Central Osteosarcoma Versus Fibrous Dysplasia.
AJSP: Reviews & Reports, 2001. 6(1): p. 22-27.
Meazza, C. and P. Scanagatta, Metastatic osteosarcoma: a challenging
multidisciplinary treatment. Expert Rev Anticancer Ther, 2016. 16(5): p. 543-56.
Daw, N.C., et al., Recurrent osteosarcoma with a single pulmonary metastasis: a
multi-institutional review. British Journal of Cancer, 2015. 112(2): p. 278-282.
Yu, D., et al., Methotrexate, doxorubicin, and cisplatinum regimen is still the
preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical
observation. Medicine, 2019. 98(19): p. e15582.
Yu, D., et al., Methotrexate, doxorubicin, and cisplatinum regimen is still the
preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical
observation. Medicine (Baltimore), 2019. 98(19): p. e15582.
Martin, J.W., J.A. Squire, and M. Zielenska, The genetics of osteosarcoma.
Sarcoma, 2012. 2012: p. 627254.
Chen, X., et al., Recurrent somatic structural variations contribute to
tumorigenesis in pediatric osteosarcoma. Cell Rep, 2014. 7(1): p. 104-12.
Moriarity, B.S., et al., A Sleeping Beauty forward genetic screen identifies new
genes and pathways driving osteosarcoma development and metastasis. Nat
Genet, 2015. 47(6): p. 615-24.
Aparisi, T., A. Stark, and J.L. Ericsson, Human osteogenic sarcoma. Study of the
ultrastructure, with special notes on the localization of alkaline and acid
phosphatase. Int Orthop, 1982. 6(3): p. 171-9.
Williams, A.H., C.P. Schwinn, and J.W. Parker, The ultrastructure of
osteosarcoma. A review of twenty cases. Cancer, 1976. 37(3): p. 1293-301.
Stewart, E., et al., Orthotopic patient-derived xenografts of paediatric solid
tumours. Nature, 2017. 549(7670): p. 96-100.
Westrate, L.M., et al., Form Follows Function: The Importance of Endoplasmic
Reticulum Shape. Annual Review of Biochemistry, 2015. 84(1): p. 791-811.
Conti, B.J., et al., Cotranslational folding inhibits translocation from within the
ribosome–Sec61 translocon complex. Nature Structural & Molecular Biology,
2014. 21(3): p. 228-235.
Braakman, I. and D.N. Hebert, Protein Folding in the Endoplasmic Reticulum.
Cold Spring Harbor Perspectives in Biology, 2013. 5(5).

67

20.

21.

22.
23.
24.
25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

Pobre, K.F.R., G.J. Poet, and L.M. Hendershot, The endoplasmic reticulum (ER)
chaperone BiP is a master regulator of ER functions: Getting by with a little help
from ERdj friends. Journal of Biological Chemistry, 2019. 294(6): p. 2098-2108.
Oikonomou, C. and L.M. Hendershot, Disposing of misfolded ER proteins: A
troubled substrate's way out of the ER. Mol Cell Endocrinol, 2020. 500: p.
110630.
Presley, J.F., et al., ER-to-Golgi transport visualized in living cells. Nature, 1997.
389(6646): p. 81-85.
Malhotra, V. and P. Erlmann, The Pathway of Collagen Secretion. Annual
Review of Cell and Developmental Biology, 2015. 31(1): p. 109-124.
Gelse, K., E. Pöschl, and T. Aigner, Collagens--structure, function, and
biosynthesis. Adv Drug Deliv Rev, 2003. 55(12): p. 1531-46.
Lamandé, S.R. and J.F. Bateman, Procollagen folding and assembly: the role of
endoplasmic reticulum enzymes and molecular chaperones. Semin Cell Dev Biol,
1999. 10(5): p. 455-64.
Nagai, N., et al., Embryonic lethality of molecular chaperone hsp47 knockout
mice is associated with defects in collagen biosynthesis. J Cell Biol, 2000. 150(6):
p. 1499-506.
Widmer, C., et al., Molecular basis for the action of the collagen-specific
chaperone Hsp47/SERPINH1 and its structure-specific client recognition. Proc
Natl Acad Sci U S A, 2012. 109(33): p. 13243-7.
Novick, P., C. Field, and R. Schekman, Identification of 23 complementation
groups required for post-translational events in the yeast secretory pathway. Cell,
1980. 21(1): p. 205-15.
Bonfanti, L., et al., Procollagen traverses the Golgi stack without leaving the
lumen of cisternae: evidence for cisternal maturation. Cell, 1998. 95(7): p. 9931003.
Neumann, N., D. Lundin, and A.M. Poole, Comparative Genomic Evidence for a
Complete Nuclear Pore Complex in the Last Eukaryotic Common Ancestor.
PLOS ONE, 2010. 5(10): p. e13241.
Schlacht, A. and J.B. Dacks, Unexpected Ancient Paralogs and an Evolutionary
Model for the COPII Coat Complex. Genome Biology and Evolution, 2015. 7(4):
p. 1098-1109.
Miller, E.A., et al., Multiple cargo binding sites on the COPII subunit Sec24p
ensure capture of diverse membrane proteins into transport vesicles. Cell, 2003.
114(4): p. 497-509.
Barlowe, C. and A. Helenius, Cargo Capture and Bulk Flow in the Early
Secretory Pathway. Annual Review of Cell and Developmental Biology, 2016.
32(1): p. 197-222.
Hariri, H., et al., Insights into the mechanisms of membrane curvature and vesicle
scission by the small GTPase Sar1 in the early secretory pathway. Journal of
molecular biology, 2014. 426(22): p. 3811-3826.
Adolf, F., et al., Scission of COPI and COPII Vesicles Is Independent of GTP
Hydrolysis. Traffic, 2013. 14(8): p. 922-932.

68

36.

37.
38.
39.

40.

41.
42.

43.
44.

45.
46.

47.
48.

49.
50.

51.
52.

53.

Stephens, D.J. and R. Pepperkok, Imaging of procollagen transport reveals
COPI-dependent cargo sorting during ER-to-Golgi transport in mammalian cells.
J Cell Sci, 2002. 115(Pt 6): p. 1149-60.
Bard, F., et al., Functional genomics reveals genes involved in protein secretion
and Golgi organization. Nature, 2006. 439(7076): p. 604-7.
Raote, I., et al., TANGO1 builds a machine for collagen export by recruiting and
spatially organizing COPII, tethers and membranes. Elife, 2018. 7.
Tanabe, T., et al., Dual function of cTAGE5 in collagen export from the
endoplasmic reticulum. Molecular Biology of the Cell, 2016. 27(13): p. 20082013.
Saito, K., et al., cTAGE5 mediates collagen secretion through interaction with
TANGO1 at endoplasmic reticulum exit sites. Mol Biol Cell, 2011. 22(13): p.
2301-8.
Antonny, B., et al., Dynamics of the COPII coat with GTP and stable analogues.
Nature Cell Biology, 2001. 3(6): p. 531-537.
Ma, W. and J. Goldberg, TANGO1/cTAGE5 receptor as a polyvalent template for
assembly of large COPII coats. Proceedings of the National Academy of
Sciences, 2016. 113(36): p. 10061-10066.
Jin, L., et al., Ubiquitin-dependent regulation of COPII coat size and function.
Nature, 2012. 482(7386): p. 495-500.
Georges, A., et al., Molecular analysis and intestinal expression of SAR1 genes
and proteins in Anderson's disease (Chylomicron retention disease). Orphanet
journal of rare diseases, 2011. 6: p. 1-1.
Melville, D.B., S. Studer, and R. Schekman, SAR1 paralogs differ biochemically
in assembly of the COPII coat. bioRxiv, 2020: p. 2020.02.09.940833.
Saito, K., M. Maeda, and T. Katada, Regulation of the Sar1 GTPase Cycle Is
Necessary for Large Cargo Secretion from the Endoplasmic Reticulum. Front Cell
Dev Biol, 2017. 5: p. 75.
Cutrona, M.B., et al., Silencing of mammalian Sar1 isoforms reveals COPIIindependent protein sorting and transport. Traffic, 2013. 14(6): p. 691-708.
Maiers, J.L., et al., The unfolded protein response mediates fibrogenesis and
collagen I secretion through regulating TANGO1 in mice. Hepatology, 2017.
65(3): p. 983-998.
Wieland, F.T., et al., The rate of bulk flow from the endoplasmic reticulum to the
cell surface. Cell, 1987. 50(2): p. 289-300.
Balch, W.E., et al., Vesicular stomatitis virus glycoprotein is sorted and
concentrated during export from the endoplasmic reticulum. Cell, 1994. 76(5): p.
841-52.
Pagano, A., et al., Sec24 Proteins and Sorting at the Endoplasmic Reticulum *.
Journal of Biological Chemistry, 1999. 274(12): p. 7833-7840.
Tang, B.L., et al., A Family of Mammalian Proteins Homologous to Yeast Sec24p.
Biochemical and Biophysical Research Communications, 1999. 258(3): p. 679684.
Miller, E., et al., Cargo selection into COPII vesicles is driven by the Sec24p
subunit. Embo j, 2002. 21(22): p. 6105-13.

69

54.

55.
56.
57.

58.

59.
60.

61.

62.
63.

64.

65.

66.

67.

68.

69.

Mancias, J.D. and J. Goldberg, Structural basis of cargo membrane protein
discrimination by the human COPII coat machinery. The EMBO Journal, 2008.
27(21): p. 2918-2928.
Sarmah, S., et al., Sec24D-dependent transport of extracellular matrix proteins is
required for zebrafish skeletal morphogenesis. PLoS One, 2010. 5(4): p. e10367.
Baines, A.C., et al., Disruption of the Sec24d gene results in early embryonic
lethality in the mouse. PLoS One, 2013. 8(4): p. e61114.
Yoshihisa, T., C. Barlowe, and R. Schekman, Requirement for a GTPaseactivating protein in vesicle budding from the endoplasmic reticulum. Science,
1993. 259(5100): p. 1466-1468.
Khoriaty, R., et al., Functions of the COPII gene paralogs SEC23A and SEC23B
are interchangeable in vivo. Proceedings of the National Academy of Sciences,
2018. 115(33): p. E7748-E7757.
Boyadjiev, S.A., et al., Cranio-lenticulo-sutural dysplasia associated with defects
in collagen secretion. Clin Genet, 2011. 80(2): p. 169-76.
Lang, M.R., et al., Secretory COPII coat component Sec23a is essential for
craniofacial chondrocyte maturation. Nature Genetics, 2006. 38(10): p. 11981203.
Schwarz, K., et al., Mutations affecting the secretory COPII coat component
SEC23B cause congenital dyserythropoietic anemia type II. Nature Genetics,
2009. 41(8): p. 936-940.
Schwartz, T., Functional insights from studies on the structure of the nuclear pore
and coat protein complexes. Cold Spring Harb Perspect Biol, 2013. 5(7).
Niu, X., et al., Sec13 safeguards the integrity of the endoplasmic reticulum and
organogenesis of the digestive system in zebrafish. Developmental Biology, 2012.
367(2): p. 197-207.
Stankewich, M.C., P.R. Stabach, and J.S. Morrow, Human Sec31B: a family of
new mammalian orthologues of yeast Sec31p that associate with the COPII coat.
Journal of Cell Science, 2006. 119(5): p. 958-969.
Fliss, M.S., P.M. Hinkle, and C. Bancroft, Expression Cloning and
Characterization of PREB (Prolactin Regulatory Element Binding), a Novel WD
Motif DNA-Binding Protein with a Capacity to Regulate Prolactin Promoter
Activity. Molecular Endocrinology, 1999. 13(4): p. 644-657.
Nakano, A., D. Brada, and R. Schekman, A membrane glycoprotein, Sec12p,
required for protein transport from the endoplasmic reticulum to the Golgi
apparatus in yeast. Journal of Cell Biology, 1988. 107(3): p. 851-863.
Barlowe, C. and R. Schekman, SEC12 encodes a guanine-nucleotide-exchange
factor essential for transport vesicle budding from the ER. Nature, 1993.
365(6444): p. 347-9.
Weissman, J.T., H. Plutner, and W.E. Balch, The Mammalian Guanine Nucleotide
Exchange Factor mSec12 is Essential for Activation of the Sar1 GTPase
Directing Endoplasmic Reticulum Export. Traffic, 2001. 2(7): p. 465-475.
Connerly, P.L., et al., Sec16 is a Determinant of Transitional ER Organization.
Current Biology, 2005. 15(16): p. 1439-1447.

70

70.

71.
72.

73.

74.

75.

76.
77.
78.
79.
80.
81.

82.
83.
84.
85.

86.

87.
88.

Bhattacharyya, D. and B.S. Glick, Two mammalian Sec16 homologues have
nonredundant functions in endoplasmic reticulum (ER) export and transitional
ER organization. Mol Biol Cell, 2007. 18(3): p. 839-49.
Sprangers, J. and C. Rabouille, SEC16 in COPII coat dynamics at ER exit sites.
Biochem Soc Trans, 2015. 43(1): p. 97-103.
Budnik, A., K.J. Heesom, and D.J. Stephens, Characterization of human Sec16B:
indications of specialized, non-redundant functions. Scientific Reports, 2011.
1(1): p. 77.
Yorimitsu, T. and K. Sato, Insights into structural and regulatory roles of Sec16
in COPII vesicle formation at ER exit sites. Molecular Biology of the Cell, 2012.
23(15): p. 2930-2942.
Maeda, M., T. Katada, and K. Saito, TANGO1 recruits Sec16 to coordinately
organize ER exit sites for efficient secretion. J Cell Biol, 2017. 216(6): p. 17311743.
Appenzeller-Herzog, C. and H.-P. Hauri, The ER-Golgi intermediate
compartment (ERGIC): in search of its identity and function. Journal of Cell
Science, 2006. 119(11): p. 2173-2183.
Santos, A.J.M., et al., TANGO1 recruits ERGIC membranes to the endoplasmic
reticulum for procollagen export. eLife, 2015. 4: p. e10982.
Gerst, J.E., SNARE regulators: matchmakers and matchbreakers. Biochimica et
Biophysica Acta (BBA) - Molecular Cell Research, 2003. 1641(2): p. 99-110.
Mossessova, E., L.C. Bickford, and J. Goldberg, SNARE Selectivity of the COPII
Coat. Cell, 2003. 114(4): p. 483-495.
Bonifacino, J.S. and B.S. Glick, The Mechanisms of Vesicle Budding and Fusion.
Cell, 2004. 116(2): p. 153-166.
Schegg, B., et al., Core glycosylation of collagen is initiated by two beta(1O)galactosyltransferases. Mol Cell Biol, 2009. 29(4): p. 943-52.
Boyle, J., Molecular biology of the cell, 5th edition by B. Alberts, A. Johnson, J.
Lewis, M. Raff, K. Roberts, and P. Walter. Biochemistry and Molecular Biology
Education, 2008. 36(4): p. 317-318.
Rothman, J.E. and F.T. Wieland, Protein Sorting by Transport Vesicles. Science,
1996. 272(5259): p. 227-234.
Luini, A., A brief history of the cisternal progression-maturation model. Cellular
logistics, 2011. 1(1): p. 6-11.
Canty, E.G. and K.E. Kadler, Procollagen trafficking, processing and
fibrillogenesis. J Cell Sci, 2005. 118(Pt 7): p. 1341-53.
Canty-Laird, E.G., Y. Lu, and K.E. Kadler, Stepwise proteolytic activation of type
I procollagen to collagen within the secretory pathway of tendon fibroblasts in
situ. Biochem J, 2012. 441(2): p. 707-17.
Wiest, D.L., et al., Membrane biogenesis during B cell differentiation: most
endoplasmic reticulum proteins are expressed coordinately. The Journal of cell
biology, 1990. 110(5): p. 1501-1511.
Read, A. and M. Schröder, The Unfolded Protein Response: An Overview.
Biology (Basel), 2021. 10(5).
Hetz, C., K. Zhang, and R.J. Kaufman, Mechanisms, regulation and functions of
the unfolded protein response. Nat Rev Mol Cell Biol, 2020. 21(8): p. 421-438.

71

89.

90.
91.

92.
93.

94.

95.

96.
97.

98.

99.

100.
101.
102.
103.

104.

105.

Carrara, M., et al., Noncanonical binding of BiP ATPase domain to Ire1 and Perk
is dissociated by unfolded protein CH1 to initiate ER stress signaling. eLife,
2015. 4: p. e03522.
Xu, J., et al., ER stress drives ER-to-Golgi trafficking of ATF6 by blocking its
membrane insertion. bioRxiv, 2019: p. 822965.
Asada, R., et al., The signalling from endoplasmic reticulum-resident bZIP
transcription factors involved in diverse cellular physiology. The Journal of
Biochemistry, 2011. 149(5): p. 507-518.
Kondo, S., et al., Activation of OASIS family, ER stress transducers, is dependent
on its stabilization. Cell Death & Differentiation, 2012. 19(12): p. 1939-1949.
Murakami, T., et al., Signalling mediated by the endoplasmic reticulum stress
transducer OASIS is involved in bone formation. Nat Cell Biol, 2009. 11(10): p.
1205-11.
Fox, R.M., C.D. Hanlon, and D.J. Andrew, The CrebA/Creb3-like transcription
factors are major and direct regulators of secretory capacity. J Cell Biol, 2010.
191(3): p. 479-92.
Guillemyn, B., et al., A homozygous pathogenic missense variant broadens the
phenotypic and mutational spectrum of CREB3L1-related osteogenesis
imperfecta. Human Molecular Genetics, 2019. 28(11): p. 1801-1809.
Keller, R.B., et al., Monoallelic and biallelic CREB3L1 variant causes mild and
severe osteogenesis imperfecta, respectively. Genet Med, 2018. 20(4): p. 411-419.
Saito, A., et al., Regulation of endoplasmic reticulum stress response by a
BBF2H7-mediated Sec23a pathway is essential for chondrogenesis. Nature Cell
Biology, 2009. 11(10): p. 1197-1204.
Kondo, S., et al., BBF2H7, a Novel Transmembrane bZIP Transcription Factor,
Is a New Type of Endoplasmic Reticulum Stress Transducer. Molecular and
Cellular Biology, 2007. 27(5): p. 1716-1729.
Ishikawa, T., et al., UPR transducer BBF2H7 allows export of type II collagen in
a cargo- and developmental stage–specific manner. Journal of Cell Biology,
2017. 216(6): p. 1761-1774.
Durfee, R.A., M. Mohammed, and H.H. Luu, Review of Osteosarcoma and
Current Management. Rheumatol Ther, 2016. 3(2): p. 221-243.
Kansara, M., et al., Translational biology of osteosarcoma. Nature Reviews
Cancer, 2014. 14(11): p. 722-735.
Florencio-Silva, R., et al., Biology of Bone Tissue: Structure, Function, and
Factors That Influence Bone Cells. Biomed Res Int, 2015. 2015: p. 421746.
Sommerfeldt, D.W. and C.T. Rubin, Biology of bone and how it orchestrates the
form and function of the skeleton. Eur Spine J, 2001. 10 Suppl 2(Suppl 2): p. S8695.
Ben Shoham, A., et al., Deposition of collagen type I onto skeletal endothelium
reveals a new role for blood vessels in regulating bone morphology.
Development, 2016. 143(21): p. 3933-3943.
Horiuchi, K., T. Tohmonda, and H. Morioka, The unfolded protein response in
skeletal development and homeostasis. Cell Mol Life Sci, 2016. 73(15): p. 285169.

72

106.
107.
108.
109.

110.

111.
112.

113.
114.
115.
116.

117.

118.
119.
120.

121.

122.
123.

Jang, W.G., et al., BMP2 protein regulates osteocalcin expression via Runx2mediated Atf6 gene transcription. J Biol Chem, 2012. 287(2): p. 905-15.
Kadler, K.E., Fell Muir Lecture: Collagen fibril formation in vitro and in vivo. Int
J Exp Pathol, 2017. 98(1): p. 4-16.
Gorur, A., et al., COPII-coated membranes function as transport carriers of
intracellular procollagen I. J Cell Biol, 2017. 216(6): p. 1745-1759.
Lorenz, S., et al., Unscrambling the genomic chaos of osteosarcoma reveals
extensive transcript fusion, recurrent rearrangements and frequent novel TP53
aberrations. Oncotarget, 2016. 7(5): p. 5273-88.
Perry, J.A., et al., Complementary genomic approaches highlight the PI3K/mTOR
pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A,
2014. 111(51): p. E5564-73.
Rickel, K., F. Fang, and J. Tao, Molecular genetics of osteosarcoma. Bone, 2017.
102: p. 69-79.
Behjati, S., et al., Recurrent mutation of IGF signalling genes and distinct
patterns of genomic rearrangement in osteosarcoma. Nat Commun, 2017. 8: p.
15936.
Sayles, L.C., et al., Genome-Informed Targeted Therapy for Osteosarcoma.
Cancer Discov, 2019. 9(1): p. 46-63.
Weekes, D., et al., Regulation of osteosarcoma cell lung metastasis by the cFos/AP-1 target FGFR1. Oncogene, 2016. 35(22): p. 2852-2861.
Isakoff, M.S., et al., Osteosarcoma: Current Treatment and a Collaborative
Pathway to Success. J Clin Oncol, 2015. 33(27): p. 3029-35.
Steiner, G.C., M. Forest, and M.C. Vacher-Lavenu, Ultrastructure of low-grade
intraosseous osteosarcoma of bone: a comparative study with fibrous dysplasia
and parosteal osteosarcoma. Ultrastruct Pathol, 2006. 30(4): p. 293-9.
Dass, C.R., et al., A novel orthotopic murine model provides insights into cellular
and molecular characteristics contributing to human osteosarcoma. Clin Exp
Metastasis, 2006. 23(7-8): p. 367-80.
Zhou, X., et al., Exploring genomic alteration in pediatric cancer using
ProteinPaint. Nature Genetics, 2016. 48(1): p. 4-6.
Tanenbaum, M.E., et al., A protein-tagging system for signal amplification in
gene expression and fluorescence imaging. Cell, 2014. 159(3): p. 635-46.
Behnke, J. and L.M. Hendershot, The large Hsp70 Grp170 binds to unfolded
protein substrates in vivo with a regulation distinct from conventional Hsp70s. J
Biol Chem, 2014. 289(5): p. 2899-907.
Ma, Y., et al., Two distinct stress signaling pathways converge upon the CHOP
promoter during the mammalian unfolded protein response. J Mol Biol, 2002.
318(5): p. 1351-65.
Luu, H.H., et al., An orthotopic model of human osteosarcoma growth and
spontaneous pulmonary metastasis. Clin Exp Metastasis, 2005. 22(4): p. 319-29.
Chen, C. and X. Zhang, IRE1α-XBP1 pathway promotes melanoma progression
by regulating IL-6/STAT3 signaling. Journal of Translational Medicine, 2017.
15(1): p. 42.

73

124.

125.

126.
127.

128.

129.

130.
131.
132.
133.

134.

135.
136.
137.
138.

139.

140.

Scriven, P., et al., Activation and clinical significance of the unfolded protein
response in breast cancer. British Journal of Cancer, 2009. 101(10): p. 16921698.
Zhu, X.-J., et al., Down-regulation of C/EBP homologous protein (CHOP)
expression in gastric cardia adenocarcinoma: Their relationship with
clinicopathological parameters and prognostic significance. Clinics and Research
in Hepatology and Gastroenterology, 2015. 39(3): p. 391-398.
Samanta, S., et al., Clinicopathological significance of endoplasmic reticulum
stress proteins in ovarian carcinoma. Scientific Reports, 2020. 10(1): p. 2160.
Harnoss, J.M., et al., IRE1α Disruption in Triple-Negative Breast Cancer
Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and
Remodeling the Tumor Microenvironment. Cancer Research, 2020. 80(11): p.
2368-2379.
Ozawa, K., et al., Regulation of Tumor Angiogenesis by Oxygen-regulated
Protein 150, an Inducible Endoplasmic Reticulum Chaperone. Cancer Research,
2001. 61(10): p. 4206-4213.
Yuan, L., et al., TANGO1 and SEC12 are copackaged with procollagen I to
facilitate the generation of large COPII carriers. Proc Natl Acad Sci U S A,
2018. 115(52): p. E12255-e12264.
Sasaki, N., et al., cTAGE5 acts as a Sar1 GTPase regulator for collagen export.
bioRxiv, 2018: p. 452904.
Saito, K. and T. Katada, Mechanisms for exporting large-sized cargoes from the
endoplasmic reticulum. Cell Mol Life Sci, 2015. 72(19): p. 3709-20.
Boyadjiev, S.A., et al., Cranio-lenticulo-sutural dysplasia associated with defects
in collagen secretion. Clinical genetics, 2011. 80(2): p. 169-176.
Boyadjiev, S.A., et al., Cranio-lenticulo-sutural dysplasia is caused by a SEC23A
mutation leading to abnormal endoplasmic-reticulum-to-Golgi trafficking. Nature
Genetics, 2006. 38(10): p. 1192-1197.
Garbes, L., et al., Mutations in SEC24D, encoding a component of the COPII
machinery, cause a syndromic form of osteogenesis imperfecta. Am J Hum Genet,
2015. 96(3): p. 432-9.
Marini, J.C., et al., Osteogenesis imperfecta. Nature Reviews Disease Primers,
2017. 3(1): p. 17052.
Fath, S., et al., Structure and organization of coat proteins in the COPII cage.
Cell, 2007. 129(7): p. 1325-36.
Kondo, S., et al., OASIS, a CREB/ATF-family member, modulates UPR signalling
in astrocytes. Nat Cell Biol, 2005. 7(2): p. 186-94.
Vellanki, R.N., L. Zhang, and A. Volchuk, OASIS/CREB3L1 is induced by
endoplasmic reticulum stress in human glioma cell lines and contributes to the
unfolded protein response, extracellular matrix production and cell migration.
PLoS One, 2013. 8(1): p. e54060.
Bisnett, B.J., et al., Export Control: Post-transcriptional Regulation of the COPII
Trafficking Pathway. Frontiers in Cell and Developmental Biology, 2021.
8(1768).
Dallas, S.L., M. Prideaux, and L.F. Bonewald, The Osteocyte: An Endocrine Cell
… and More. Endocrine Reviews, 2013. 34(5): p. 658-690.

74

141.
142.
143.

144.
145.

146.

147.

148.

149.
150.

151.

152.

153.

154.
155.

156.

Rutkovskiy, A., K.O. Stensløkken, and I.J. Vaage, Osteoblast Differentiation at a
Glance. Med Sci Monit Basic Res, 2016. 22: p. 95-106.
Sawa, N., et al., Alternating Differentiation and Dedifferentiation between Mature
Osteoblasts and Osteocytes. Scientific Reports, 2019. 9(1): p. 13842.
Mohseny, A.B., et al., Functional characterization of osteosarcoma cell lines
provides representative models to study the human disease. Laboratory
Investigation, 2011. 91(8): p. 1195-1205.
Winkler, J., et al., Concepts of extracellular matrix remodelling in tumour
progression and metastasis. Nature Communications, 2020. 11(1): p. 5120.
Mellor, P., et al., CREB3L1 is a metastasis suppressor that represses expression
of genes regulating metastasis, invasion, and angiogenesis. Molecular and
cellular biology, 2013. 33(24): p. 4985-4995.
Rose, M., et al., OASIS/CREB3L1 is epigenetically silenced in human bladder
cancer facilitating tumor cell spreading and migration in vitro. Epigenetics, 2014.
9(12): p. 1626-40.
Ward, A.K., et al., Epigenetic silencing of CREB3L1 by DNA methylation is
associated with high-grade metastatic breast cancers with poor prognosis and is
prevalent in triple negative breast cancers. Breast Cancer Research, 2016. 18(1):
p. 12.
Boyce, B.F., Z. Yao, and L. Xing, Osteoclasts have multiple roles in bone in
addition to bone resorption. Critical reviews in eukaryotic gene expression, 2009.
19(3): p. 171-180.
Kuhn, L.T., Bone Mineralization, in Encyclopedia of Materials: Science and
Technology, K.H.J. Buschow, et al., Editors. 2001, Elsevier: Oxford. p. 787-794.
Bottini, M., et al., Matrix vesicles from chondrocytes and osteoblasts: Their
biogenesis, properties, functions and biomimetic models. Biochim Biophys Acta
Gen Subj, 2018. 1862(3): p. 532-546.
Deatherage, B.L., B.T. Cookson, and H.L. Andrews-Polymenis, Membrane
Vesicle Release in Bacteria, Eukaryotes, and Archaea: a Conserved yet
Underappreciated Aspect of Microbial Life. Infection and Immunity, 2012. 80(6):
p. 1948-1957.
van Niel, G., G. D'Angelo, and G. Raposo, Shedding light on the cell biology of
extracellular vesicles. Nature Reviews Molecular Cell Biology, 2018. 19(4): p.
213-228.
Davies, O.G., et al., Osteoblast-Derived Vesicle Protein Content Is Temporally
Regulated During Osteogenesis: Implications for Regenerative Therapies. Front
Bioeng Biotechnol, 2019. 7: p. 92.
Shapiro, I.M., W.J. Landis, and M.V. Risbud, Matrix vesicles: Are they anchored
exosomes? Bone, 2015. 79: p. 29-36.
Bilen, M.A., et al., Proteomics Profiling of Exosomes from Primary Mouse
Osteoblasts under Proliferation versus Mineralization Conditions and
Characterization of Their Uptake into Prostate Cancer Cells. J Proteome Res,
2017. 16(8): p. 2709-2728.
Cui, Y., et al., Exosomes derived from mineralizing osteoblasts promote ST2 cell
osteogenic differentiation by alteration of microRNA expression. FEBS Letters,
2016. 590(1): p. 185-192.

75

157.

158.
159.

160.

161.

162.
163.

164.
165.

166.
167.

168.
169.
170.

171.
172.

173.

Lyu, H., et al., The Role of Bone-Derived Exosomes in Regulating Skeletal
Metabolism and Extraosseous Diseases. Frontiers in Cell and Developmental
Biology, 2020. 8(89).
Jung, T., et al., CD44v6 dependence of premetastatic niche preparation by
exosomes. Neoplasia, 2009. 11(10): p. 1093-105.
Janowska-Wieczorek, A., et al., Microvesicles derived from activated platelets
induce metastasis and angiogenesis in lung cancer. Int J Cancer, 2005. 113(5): p.
752-60.
Macklin, R., et al., Extracellular vesicles secreted by highly metastatic clonal
variants of osteosarcoma preferentially localize to the lungs and induce
metastatic behaviour in poorly metastatic clones. Oncotarget, 2016. 7(28): p.
43570-43587.
Raimondi, L., et al., Osteosarcoma cell-derived exosomes affect tumor
microenvironment by specific packaging of microRNAs. Carcinogenesis, 2020.
41(5): p. 666-677.
Binns, D., et al., QuickGO: a web-based tool for Gene Ontology searching.
Bioinformatics, 2009. 25(22): p. 3045-6.
Zhou, J.Y., et al., Galectin-3 is a candidate biomarker for amyotrophic lateral
sclerosis: discovery by a proteomics approach. J Proteome Res, 2010. 9(10): p.
5133-41.
Li, I. and B.Y. Nabet, Exosomes in the tumor microenvironment as mediators of
cancer therapy resistance. Molecular Cancer, 2019. 18(1): p. 32.
Xu, R., et al., Extracellular vesicles in cancer — implications for future
improvements in cancer care. Nature Reviews Clinical Oncology, 2018. 15(10):
p. 617-638.
Gomez-Navarro, N. and E. Miller, Protein sorting at the ER–Golgi interface.
Journal of Cell Biology, 2016. 215(6): p. 769-778.
Peñalver, E., et al., Clathrin and two components of the COPII complex, Sec23p
and Sec24p, could be involved in endocytosis of the Saccharomyces cerevisiae
maltose transporter. Journal of bacteriology, 1999. 181(8): p. 2555-2563.
Henne, William M., Nicholas J. Buchkovich, and Scott D. Emr, The ESCRT
Pathway. Developmental Cell, 2011. 21(1): p. 77-91.
Luini, A., et al., Morphogenesis of post-Golgi transport carriers. Histochem Cell
Biol, 2008. 129(2): p. 153-61.
McGee, A.M., et al., The mitochondrial protein C1qbp promotes cell
proliferation, migration and resistance to cell death. Cell Cycle, 2011. 10(23): p.
4119-4127.
Kim, K., et al., C1QBP is upregulated in colon cancer and binds to
apolipoprotein A-I. Exp Ther Med, 2017. 13(5): p. 2493-2500.
Shi, H., et al., Complement component 1, q subcomponent binding protein
(C1QBP) in lipid rafts mediates hepatic metastasis of pancreatic cancer by
regulating IGF-1/IGF-1R signaling. International Journal of Cancer, 2017.
141(7): p. 1389-1401.
Chen, Y.B., et al., Increased expression of hyaluronic acid binding protein 1 is
correlated with poor prognosis in patients with breast cancer. J Surg Oncol,
2009. 100(5): p. 382-6.

76

174.

175.
176.

177.
178.

179.
180.

181.

182.
183.

184.

185.

186.
187.

188.
189.
190.

Veliceasa, D., et al., Transient potential receptor channel 4 controls
thrombospondin-1 secretion and angiogenesis in renal cell carcinoma. Febs j,
2007. 274(24): p. 6365-77.
Huang, T., et al., Thrombospondin-1 is a multifaceted player in tumor
progression. Oncotarget, 2017. 8(48): p. 84546-84558.
Rosini, S., et al., Thrombospondin-1 promotes matrix homeostasis by interacting
with collagen and lysyl oxidase precursors and collagen cross-linking sites.
Science Signaling, 2018. 11(532): p. eaar2566.
Jiménez, B., et al., Signals leading to apoptosis-dependent inhibition of
neovascularization by thrombospondin-1. Nature Medicine, 2000. 6(1): p. 41-48.
Dawson, D.W., et al., CD36 Mediates the In Vitro Inhibitory Effects of
Thrombospondin-1 on Endothelial Cells. Journal of Cell Biology, 1997. 138(3): p.
707-717.
Carminati, L. and G. Taraboletti, Thrombospondins in bone remodeling and
metastatic bone disease. Am J Physiol Cell Physiol, 2020. 319(6): p. C980-c990.
Hu, C., et al., Thrombospondin-1 promotes cell migration, invasion and lung
metastasis of osteosarcoma through FAK dependent pathway. Oncotarget, 2017.
8(44): p. 75881-75892.
Nahar, N.N., et al., Matrix vesicles are carriers of bone morphogenetic proteins
(BMPs), vascular endothelial growth factor (VEGF), and noncollagenous matrix
proteins. Journal of Bone and Mineral Metabolism, 2008. 26(5): p. 514-519.
Jeppesen, D.K., et al., Reassessment of Exosome Composition. Cell, 2019. 177(2):
p. 428-445.e18.
Jerez, S., et al., Proteomic Analysis of Exosomes and Exosome-Free Conditioned
Media From Human Osteosarcoma Cell Lines Reveals Secretion of Proteins
Related to Tumor Progression. Journal of Cellular Biochemistry, 2017. 118(2): p.
351-360.
Davies, O.G., et al., Annexin-enriched osteoblast-derived vesicles act as an
extracellular site of mineral nucleation within developing stem cell cultures.
Scientific Reports, 2017. 7(1): p. 12639.
Wei, Y., et al., Extracellular vesicles derived from the mid-to-late stage of
osteoblast differentiation markedly enhance osteogenesis in vitro and in vivo.
Biochemical and Biophysical Research Communications, 2019. 514(1): p. 252258.
Shi, Y., et al., Roles of secreted frizzled-related proteins in cancer. Acta
Pharmacol Sin, 2007. 28(9): p. 1499-504.
Talbot, L.J., et al., A Novel Orthotopic Implantation Technique for Osteosarcoma
Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of
B7-H3-CAR T Cells. Front Immunol, 2021. 12: p. 691741.
Szymanski, W.G., et al., Cytoskeletal Components Define Protein Location to
Membrane Microdomains. Mol Cell Proteomics, 2015. 14(9): p. 2493-509.
Chen, Z., et al., Cytoskeleton-centric protein transportation by exosomes
transforms tumor-favorable macrophages. Oncotarget, 2016. 7(41).
Tomoishi, S., et al., CREB3L2-mediated expression of Sec23A/Sec24D is involved
in hepatic stellate cell activation through ER-Golgi transport. Sci Rep, 2017.
7(1): p. 7992.

77

191.

Faustino-Rocha, A., et al., Estimation of rat mammary tumor volume using
caliper and ultrasonography measurements. Lab Animal, 2013. 42(6): p. 217224.

78

APPENDIX A. CHAPTER 2 SUPPLEMENTAL DATA

Table A-1.

Reverse transcription and qRT-PCR primer pairs.

Table A-2.

Plasmid constructs.
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Table A-3.

gRNA design.

Thanks to the Center for Advanced Genome Engineering (CAGE) at St. Jude Children’s
Research Hospital for gRNA designs. The CAGE is funded in part by the National
Cancer Institute of the National Institutes of Health under Award Number P30CA021765.
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Figure A-1.
samples.

Collagen-I RNA expression is physiologically normal in most patient

Heatmap displays log2 FPKM values of normal osteoblast tissue and SJOS patient tumor
samples for COL1A1 and COL1A2 transcripts. Normal tissue, n=2 and patient tumor
samples, n=1.
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Table A-4.

Fold change of genes involved in collagen I secretion.

The table displays the averaged fold change of RNA transcripts from 108 OS patients.
This PeCan RNA expression data was normalized to human osteoblast tissue, n=2. Fold
change values <-5.0 are annotated as decreased and >+5.0 are considered increased
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Figure A-2.
collagen-I.

Transient expression of COPII genes restores ability to secrete

SaOS2 cells were transfected with 1ug of SEC24D and SAR1A constructs either
individually or in combination. 48hrs post-transfection cells were 35S labeled, conditioned
media harvested, and cells lysed in NP40 buffer. Both lysate and media were
immunoprecipitated with anti-collagen-I serum (anti-SP1.D8) and analyzed by reduced
SDS-PAGE.
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Figure A-3.

COPII genes are not epigenetically silenced.

(A,B) Genomic location and corresponding ChIP-seq data for SAR1A and SEC24D
genes from OS-PDX. The chromHMM for each region of the gene are provided about the
ChIP-seq peaks, and the scale for the ChIP-seq is indicated on the side of each track.
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Figure A-4.

SunTag CRISPR activation of engineered cell lines.
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Figure A-5.

CREB3L1 is expressed in the majority of 108 OS tumor samples.

(A) RNA-Seq analyses of COPII transcripts consist of three OS cell lines normalized to
hFOB1.19, n=3. (B) The scatter plot displays the log2 fold change of CREB3L1
transcripts from 108 OS patient tumor samples. The (black) midline bar plots the mean of
the group. The PeCan RNA expression data was normalized to human osteoblast tissue,
n=2.
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APPENDIX B. CHAPTER 3 SUPPLEMENTAL DATA

Figure B-1.

Minimal UPR induction after 24hr serum free incubation.

Cells were incubated in serum free medium for the indicated timepoints. The 3hr
thapsigargin sample was included as a UPR inducing control. Samples were harvested,
reverse transcribed, and subjected qRT-PCR analysis for UPR activation markers of
XBP1s and CHOP, n=1.

Figure B-2.

Proliferation is not affected by COPII restoration.

SaOS2.ST(-/+COPII) cells and 143B.ST(-/+COPII) were plated in a 96-well format and
were analyzed in triplicate every 24h for a total of 96h for the conversion of MTS into
soluble formazan. After 1h incubation period OD was measured on an ELISA plate
reader and background subtracted. Statistical differences of the assay were computed
using unpaired, two-tailed Student’s t-tests of each timepoint and were discovered to be
non-significant of SaOS2.ST vs SaOS2+COPII and 143B.ST vs 143B+COPII. Error bars
indicate mean ± SD of absorbance 490nm for OD readings, n=3.
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Figure B-3.
cells.

Invasion abilities are not significantly altered in COPII restored OS

SaOS2(-/+COPII) or 143B(-/+COPII) were plated at equivalent density in a collagen-I
invasion chamber absent of serum. Lower chamber medium contained 10% serum and
invasion was analyzed 24h later by optical density according to the assay protocol.
Statistical differences of the assay were computed using unpaired, two-tailed Student’s ttests and Welch’s correction, and are indicated as ns= non-significant findings, n=3. Error
bars indicate mean ± SD of absorbance 560nm for OD readings.
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Figure B-4.

COPII restoration does not affect in vivo tumor growth of OS cells.

100K cells of 143B.ST or 143B+COPII were implanted into the right tibia of CD1-nude
mice, n=10. (A) On day 3 post-implant luciferase signal was first measured and every 7d
forward to monitor tumor growth. Total bioluminescence flux of the region of interest
(right tibia) was plotted against days post-implant. (B) Caliper measurements were
recorded in supplement to luciferase imaging and tumor volume calculated. Statistical
differences of both the luciferase signal and tumor volume were computed using
unpaired, two-tailed Student’s t-tests of each timepoint comparison and group overall and
were discovered to be non-significant. Error bars indicate mean ± SD.

89

APPENDIX C. CHAPTER 3 SUPPLEMENTAL METHODS

Serum Free UPR Induction Test
143B.ST and 143B.ST+COPII cells were seeded 24h prior and upon achieving
~70% confluency were incubated in serum free medium for the indicated timepoints. As
a control, cells also were treated with a final concentration of 1uM Thapsigargin (SigmaAldrich) by addition to the cell medium for 3hrs. All samples were harvested, washed 2x
with PBS and cell pellets preserved at -20°C until further sample processing.

Real-Time PCR
Total RNA was isolated using the RNeasy Kit (Qiagen) from cell pellets. RNA
was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems) and subjected to SYBR® Green chemistry-based qPCR according
to the manufacturer's protocol using the QuantStudio 3 Real-time PCR System (Applied
Biosystems). Primer pairs were obtained from (ThermoFisher Scientific) and sequences
are listed in (Table A-3). Relative mRNA fold change was computed from the
QuantStudio-generated Ct values by using the 2−ΔΔCt method. Hour zero mRNA levels
were normalized to 1, and additional timepoints mRNA levels were plotted as a relative
measure to hour zero.

Proliferation Assay
SaOS2(-/+COPII) cells were plated at 5K cells/well and 143B(-/+COPII) cells
were plated at 3K cells/well in a 96-well format. Samples were analyzed in triplicate
every 24h for a total of 96h for the conversion of MTS into soluble formazan (Promega
#G5421). After 1h incubation period OD was measured on an ELISA plate reader and
background subtracted. Statistical differences of the assay were computed using unpaired,
two-tailed Student’s t-tests of each timepoint and were discovered to be non-significant
of SaOS2.ST vs SaOS2+COPII and 143B.ST vs 143B+COPII. Error bars indicate mean
± SD of 490nm OD readings, n=3.

Invasion Assay
SaOS2(-/+COPII) or 143B(-/+COPII) were plated at equivalent density in a
collagen-I invasion chamber absent of serum (Cell BioLabs#CBA-110-COL). Lower
chamber medium contained 10% serum and invasion was analyzed 24h later by optical
density according to the assay protocol. Statistical differences of the assay were
computed using unpaired, two-tailed Student’s t-tests and Welch’s correction, and are
indicated as ns= non-significant findings, n=3. Error bars indicate mean ± SEM of 560nm
OD readings.
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Orthotopic Xenograft
Homozygous CD1-Nude mice purchased from Charles River were housed and
cared for in accordance with both the Animal Use and Care Committee and the Animal
Research Center at St. Jude Children's Research Hospital, adhering to the National
Institutes of Health guidelines. 100K 143B.ST or 143B.ST(+COPII) cells were implanted
into the right proximal anterior tibia of mice by Dr. Lindsey Talbot via her novel
orthotopic implantation method [187].

IVIS Bioluminescence Imaging
Beginning 3d post-surgery, tumor implantation and growth was monitored weekly
by bioluminescent imaging according to SJCRH protocol. 5-10 minutes prior to imaging,
animals were injected (IP) with D-Luciferin (15 mg/ml in sterile saline) at a dose of 150
mg/kg (10 µL/g of body weight). After administration, animals were anesthetized using
Isoflurane (1.5-2% delivered in 100% O2 at 1 l/min) and maintained via nosecone on
heated imaging bed within the system for the duration of the scan. Following imaging,
animals were allowed to recover on a heating blanket under observation and
supplemented with oxygen as required.

Tumor Volume
In supplement to bioluminescent imaging caliper measurements of the width and
length of palpable tumors were recorded weekly. Tumor volume was calculated
according to the formula V = (W2 × L)/2 [191].

RNA-Sequencing
RNA-seq was performed by the Genome Sequencing Facility at St. Jude
Children’s Research Hospital. RNA was quantified using the Quant-iT RiboGreen assay
(Life Technologies) and quality checked by 2100 Bioanalyzer RNA 6000 Nano assay
(Agilent,) 4200 TapeStation High Sensitivity RNA ScreenTape assay (Agilent,) or
LabChip RNA Pico Sensitivity assay (PerkinElmer) prior to library generation. Libraries
were prepared from total RNA with the TruSeq Stranded Total RNA Library Prep Kit
according to the manufacturer’s instructions (Illumina, PN 20020599). Libraries were
analyzed for insert size distribution on a 2100 BioAnalyzer High Sensitivity kit (Agilent
Technologies,) 4200 TapeStation D1000 ScreenTape assay (Agilent Technologies,) or
Caliper LabChip GX DNA High Sensitivity Reagent Kit (PerkinElmer.) Libraries were
quantified using the Quant-iT PicoGreen ds DNA assay (Life Technologies) or low pass
sequencing with a MiSeq nano kit (Illumina.) Paired end 100 cycle sequencing was
performed on a HiSeq 4000 (Illumina.).
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